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ABSTRACT

TREATMENT-RELATED DECISIONAL CONFLICT, QUALITY OF LIFE, AND
COMORBID ILLNESS IN OLDER ADULTS WITH CANCER

By
Jeannette M. Kates
May 2014

Dissertation supervised by Linda Goodfellow PhD, RN
As the aging population the nation increases, cancer diagnoses in this age group
will also increase. The many chronic medical conditions associated with older adults will
be confounded by a diagnosis of cancer. Older adults with cancer are at risk for physical,
psychological, and functional decline as a result of not only the cancer, but also the
cancer treatment. This study utilized a cross-sectional, descriptive, correlational study
design to explore the relationships between and among treatment-related decisional
conflict, quality of life and comorbidity in older adults with cancer. An anonymous
survey method was employed. The criteria for inclusion in this study were: (a) 65 years
of age or older, (b) English-speaking, (c) ability to read English at an eighth grade level,
(d) having a current cancer diagnosis, and (e) currently receiving cancer treatment. A
sample size of 200 was recruited for this study from outpatient medical oncology,
radiation oncology and palliative care practices in New Jersey. The participants
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completed four instruments including: (a) Decisional Conflict Scale (DCS), (b) SelfAdministered Comorbidity Questionnaire (SCQ), (c) European Organization for
Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30),
and (d) Demographic Information Form (DIF). Bivariate relationships existed between
increased levels of decisional conflict and increased quality of life (p = .009) and quality
of life and comorbidity (p = .001). All six regression models achieved significance (p <
.001). Three to five statistically significant relationships were identified in each of the six
regression models. Positive relationships existed between decisional conflict and
financial problems, physical function, and global health status/quality of life. Increased
emotional function may be predictive of decreased decisional conflict in all of the
regression models. Other negative relationships existed between decisional conflict and
cognitive function, diarrhea, spiritual support, insomnia, year diagnosed, fatigue, and
nausea/vomiting. With their focus on patient-centered care, nurses are a crucial
component of the multidisciplinary cancer team that can empower older cancer patients
to communicate their values and preferences regarding cancer treatment.
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CHAPTER 1
INTRODUCTION
1.1

Background
It is widely accepted that the single greatest risk factor for cancer is age. Sixty percent of

cancers and two-thirds of cancer deaths occur over the age of 65 years (National Cancer Institute,
2013). This proportion is expected to increase markedly in the near future due to the aging of the
population. The incidence of comorbid illness also increases with age. On average, people 65
years of age and over with cancer suffer from three additional diseases (Extermann, 2000;
Marenco et al., 2008). Comorbidity is associated with reduced life expectancy and increased risk
for treatment complications, while also having the potential to negatively affect the natural
history of cancer (Balducci, 2009; Extermann, 2007; Muss, 2009; Zeber et al., 2008).
In light of these statistics, both medicine and nursing have recognized geriatric oncology
as a specialty area within oncology (Institute of Medicine, 2007; Kagan, 2004; Lichtman,
Balducci, & Aapro, 2007; Oncology Nursing Society and Geriatric Oncology Consortium,
2007). In the nursing literature, Kagan (2004) proposed the term gero-oncology, with gero
connoting a focus on health and function and oncology as the term describing “the study of and
care for people with cancer” (p. 295). Regardless of the terminology, care of older adults with
cancer focuses specifically on the functional impact of the interplay of aging and cancer,
including the role of comorbidities (Blank & Bellizzi, 2008; Oncology Nursing Society and
Geriatric Oncology Consortium, 2007).
Although the goals of cancer treatment in cancer patients who are older —namely cure,
prolongation of survival, and effective symptom management—are the same as those for cancer
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patients of other ages, there are unique factors to consider with this population (Balducci, 2009).
Cancer management in older adults involves several questions, including:
(a) Is the patient going to die of cancer or with cancer?
(b) Is the patient going to live long enough to suffer the consequences of cancer?
(c) Is the patient able to tolerate the treatment?
(d) Are some complications of cancer treatment more common in older adults?
(e) Is the social network of the patient adequate to support him or her during the
treatment? (Balducci, 2009, p. 310)
Physiologic, functional, and psychosocial factors must be considered when answering
these questions. Clinicians must balance the implications of the cancer diagnosis with the risks
and benefits of cancer treatment on every aspect of a patient’s life.
Regardless of age, cancer treatment-related decisions can be exceedingly complex.
Individuals have varying levels of desire for participating in their decision making, which may
be influenced by their age and disease progression (Barry & Henderson, 1996; Degner & Sloan,
1992; Petrisek, Laliberte, Allen, & Mor, 1997; Yogaparan et al., 2009). Additionally, there are a
variety of psychological, physical, functional, and social factors that influence decision making
(Chen, Haley, Robinson, & Schonwetter, 2003; Gauthier & Swigart, 2003; Kelly-Powell, 1997;
Kohara & Inoue, 2010). With an increasing number of cancer treatments available, patients are
presented with increasingly difficult decisions. These decisions can lead to decisional conflict,
which can be described as “a state of uncertainty about which course of action to take when
choices among competing actions involve risk, loss, regret, or challenge to personal life values”
(Legare, O'Connor, Graham, Wells, & Tremblay, 2006, p. 374).
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Physiologic and psychological factors can be the basis for patients’ decision making. For
older adults, decisions regarding treatment may be considered in the context of physical function.
Sinding, Wiernikowski, and Aronson (2005) found that people sometimes choose to forego
treatment explicitly within the context of their age and comorbidities. Careful thought precedes
decision making, influenced by a broad perspective of older adults’ values and their perceptions
of their whole life situation (Hughes, Closs, & Clark, 2009; Thome, Dykes, Gunnars, &
Hallberg, 2003).
Quality of life (QOL) is a concept that is central to the care of cancer patients. QOL is
generally described as being subjective and multidimensional (Cella, 1992). Subjectivity refers
to the fact that QOL can be understood only from the patient’s perspective; QOL can only be
assessed appropriately by asking the patient about it directly. Patient’s responses are influenced
by their current set of expectations surrounding their actual functional level, as well as their
perceptions about the treatment environment (Cella). The multidimensional component of QOL
refers to the coverage of a broad range of content, including physical functioning or well-being,
psychological well-being, social role functioning or well-being, disease- and treatment-related
symptoms, and spiritual well-being (Cella; Dunn et al., 2003; Ferrans, 1990).
Decisional conflict is a key concept in the Ottawa Decision Support Framework (ODSF),
which guided this study (O'Connor, 2006). The ODSF asserts that the decisional needs of
patients will affect decision quality, and that decision support can improve decision quality by
addressing unresolved decisional needs. Furthermore, the ODSF asserts that decisional conflict
can be lowered with decision-supporting interventions, such as providing information about
options, benefits, risks, and side effects; helping to clarify values; and guiding through the steps
of deliberation and shared decision making (O'Connor, 2006).
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According to O’Connor (2006), decisional needs include factors such as: decision,
decisional conflict, knowledge and expectations, values, support and resources, and personal and
clinical characteristics. In addition to other personal and clinical characteristics that will be
described in further detail in Chapter 2, patients’ health status (including physical, emotional,
cognitive, and social) is an essential component in determining their decisional needs.
Measurement of comorbid illness and QOL are just two ways in which to gain some insight into
a patient’s health status and, ultimately, decisional needs. Decision quality refers to both the
quality of the decision and the quality of the decision-making process. O’Connor (2006) defines
the quality of the decision as “the extent to which the chosen option best matches informed
clients’ values for benefits, harms, and scientific uncertainties” (p. 3). Not only might these
values be influenced by patients’ perceptions of QOL, but QOL may also be influenced by
patients’ decisions and decision quality.
As the proportion of older adults in the world increases, so too will the prevalence of
cancer. Cancer treatment-related decisions are multifactorial and complex for both health care
providers and patients. Physicians utilize clinical tools in making decisions regarding treatment.
Little is known about how older adults make their own decisions regarding treatment and
whether they experience decisional conflict regarding those decisions. This study is an important
first step towards understanding the unique interplay of age, cancer, comorbid illness, QOL and
decisional conflict.
1.2

Purpose
The purpose of this study was to examine the relationships between and among

treatment-related decisional conflict, QOL, and comorbid illness, in older adults with cancer. In

4

addition, predictive analysis was used to ascertain the degree to which variability in QOL and
comorbidity affect decisional conflict in treatment-related decision making.
1.3

Research Questions
The following research questions guided this inquiry:
1. What is the relationship between and among treatment-related decisional conflict,
QOL, and comorbidity in older adults with cancer?
2. To what degree does the variability in QOL and level of comorbidity predict
decisional conflict in decision making?

1.4

Definition of Terms
The key terms used throughout this study will be defined and operationalized as follows:
1.4.1 Older adult
In most of the developed world, the chronological age of 65 years and older serves as the

definition of older adult (Feinstein, 1970). In the oncology nursing literature, Kagan (2004)
describes older adults as living “in the context of recognizing a life mostly lived” (p. 295). For
this study, older adults were defined as people who self-report a chronological age of 65 years or
older.
1.4.2 Comorbidity
Comorbidity can be described as “any distinct additional entity that has existed or may
occur during the clinical course of a patient who has the index disease under study” (Feinstein,
1970, p. 455). In this study, comorbidity was measured by the existence of medical problems in
addition to the cancer diagnosis, as reported on the Self-Administered Comorbidity
Questionnaire (SCQ) (Sangha, Stucki, Liang, Fossel, & Katz, 2003).
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1.4.3 Decisional conflict
Decisional conflict is “the uncertainty about which course of action to take when choice
among competing actions involves risk, loss, regret, or challenge to personal life values”
(O'Connor & O'Brien-Pallas, 1989, p. 573). Patients’ decisional conflict was measured in this
study using the Decisional Conflict Scale (DCS) (O'Connor, 1995) which measures:
personal perceptions of: a) uncertainty in choosing options; b) modifiable factors
contributing to uncertainty such as feeling uninformed, unclear about personal values and
unsupported in decision making; and c) effective decision making such as feeling the
choice in informed, values-based, likely to be implemented and expressing satisfaction
with the choice (O'Connor, 2010, p. 1).
1.4.4 Quality of life
The World Health Organization (1993) defines QOL as “a broad ranging concept affected
in a complex way by the person’s health, psychological state, level of independence, social
relationships, personal beliefs and their relationship to salient features of their environment” (p.
1). Cella and Cherin (1988) incorporate the subjective component when they refer to QOL as
“patients’ appraisal of and satisfaction with their current level of functioning compared to what
they perceive to be possible or ideal” (p. 72). Multidimensionality, referring to the coverage of a
broad range of content including physical functioning or well-being, psychological well-being,
social role functioning or well-being, disease- and treatment-related symptoms, and spiritual
well-being, is another fundamental component of QOL (Cella; Dunn et al., 2003; Ferrans, 1990).
In this study, QOL is cancer-specific and multidimensional and was measured by the European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) (Aaronson et al., 1993).
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1.5

Assumptions and Limitations
1.5.1 Assumptions
The following assumptions were made:
1. Older adults with cancer are at risk for decisional conflict related to cancer treatmentrelated decisions.
2. Patients responded honestly to all questions.
3. The instruments used to collect data were appropriate, sensitive, reliable, and valid
for use in this population.
1.5.2 Limitations
The limitations of the study were:
1. One geographical location in New Jersey was represented, thus limiting the
generalizability of the findings.
2. A response bias may have occurred in that those individuals who participated in the
study may be different than those who did not, thus limiting the generalizability of the
findings.

1.6

Significance
As the aging population increases, cancer diagnoses in this population will also increase.

The many chronic medical conditions associated with older adults will be confounded by a
diagnosis of cancer. Older adults with cancer are at risk for physical, psychological, and
functional decline as a result of not only the cancer, but also the cancer treatment.

By

understanding the relationship among the proposed variables, health care providers will be better
prepared to understand how to support older adults in the cancer treatment decision-making
process.
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The diagnosis of cancer is a life-altering event that has the potential to cause significant
emotional and psychological distress. Oncology nurses are charged with the responsibility of
assessing the psychosocial needs of their patients and collaborating with other disciplines to
design and implement plans to provide patients with the needed support (Institute of Medicine,
2007; Kagan, 2004; Lichtman et al., 2007; Oncology Nursing Society and Geriatric Oncology
Consortium, 2007). Feeling conflicted about decisions related to the diagnosis and its treatment
may lead patients to have further distress. By knowing how much decisional conflict occurs,
nurses and other health care providers can develop and implement strategies to minimize it.
An understanding of the context in which decisional conflict occurs is critical. The
presence of comorbidities impacts how physicians make treatment-related decisions.
Comorbidities may also affect how patients make decisions related to treatment. QOL, as a
multidimensional concept, can be affected by cancer and cancer treatment. Perception of one’s
QOL may impact the decisions that a patient makes regarding treatment (Sekeres et al., 2004);
conversely, the treatment may also impact QOL in some way.
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CHAPTER 2
REVIEW OF THE LITERATURE
The following review of the literature provided the theoretical and research background
for the issues that were addressed by the research questions. An extensive search of the
literature, including Cinahl, MEDLINE, PubMed, PsycINFO, Health and Psychosocial
Instruments database, and ProQuest Digital Dissertations was conducted to determine the current
state of literature. The initial search terms utilized were: life-threatening illness, decisionmaking process, older adults, elderly, and cancer treatment. Once the resultant literature was
reviewed, a conceptual framework and study variables were identified. Another literature search
was then conducted using the following search terms: Ottawa Decision Support Framework,
decisional conflict, decision making, comorbidity, comorbid illness, and quality of life.
2.1

Theoretical Framework
This study was guided by the Ottawa Decision Support Framework (ODSF), which

utilizes concepts and theories from general psychology, social psychology, decision analysis,
decisional conflict, values, social support, and self-efficacy (O'Connor, 2006). The ODSF is
intended for all participants involved in decision making, including the individual, family, and
health practitioner. The ODSF postulates that the improvement of the quality of decision making
may impact favorably on patients’ outcomes (Legare et al., 2006).
2.1.1 ODSF variables
The ODSF was proposed to address decisional conflict. The model includes three
variables: decisional needs, decision quality, and decision support (see Figure 1). The framework
asserts that the decisional needs of participants will affect decision quality, and that decision
support can improve decision quality by addressing unresolved decisional needs.
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Quality
Of Life

Comorbid
Illness








Decisional Needs:
Decision
Decisional conflict
Knowledge & expectations
Values
Support & resources
Personal & clinical
characteristics







Decision Quality:
Quality of the decision
Quality of the decision
making process

Decision Support:
Patient decision aids
Decision coaching

Figure 1. Modified Ottawa Decision Support Framework (ODSF). The ODSF was modified to
include the variables of comorbid illness and quality of life. These variables have been linked to
the existing ODSF as indicated by the dotted lines. From “Ottawa Decision Support Framework
to address decisional conflict,” by O’Connor, 2006, retrieved from
http://www.ohri.ca/decisionaid. Adapted with permission.
The variable of decisional needs includes factors such as: decision [type, timing, stage,
and leaning, which is defined as “the inclination to choose one option over the other”
(O'Connor, 2006, p. 3)]; decisional conflict; knowledge and expectations; values; support and
resources (others’ opinions/practices, pressure, role in decision making, experience, self-efficacy,
motivation, skill, and external support); and personal and clinical characteristics (O'Connor,
2006). The nature of the decision to be made, one’s knowledge of the health problem
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necessitating the need for the decision, cognizance of the available options and outcomes, and
perceived likelihood of outcomes of each option contribute to the variable of decisional needs.
Personal characteristics of both the patient (age, gender, education, marital status, ethnicity,
occupation, locale, diagnosis and duration of condition, health status) and practitioner (age,
gender, ethnicity, clinical education, specialty, practice locale, experience, counseling style) also
influence decisional needs (O'Connor, 2006).
Decision quality refers to both the quality of the decision and the quality of the process of
decision making. According to the ODSF, the quality of decision is “the extent to which the
chosen option best matches informed clients’ values for benefits, harms, and scientific
uncertainties” (O'Connor, 2006, p. 3). Equally important is the quality of the process of decision
making, which is:
the extent to which a person is helped to: (a) recognize that a decision needs to be made;
(b) know about the available options and associated procedures, benefits, harms,
probabilities, and scientific uncertainties; (c) understand that values affect the decision;
(d) be clear about which features of the options matter most to them (e.g. benefits, harms,
and scientific uncertainties); (e) discuss values with their clinician(s); and (f) become
involved in decision making in ways they prefer. (O'Connor, 2006, p. 3)
Decision quality affects actions or behavior, health outcomes, emotions, and the appropriate use
of health services (O'Connor, 2006). The ODSF postulates that decision support, in the form of
clinical counseling, decision aides, and coaching, can address unresolved decisional needs, thus
improving decision quality.
2.1.2 Decisional conflict
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The ODSF was derived from the construct of decisional conflict (O'Connor, 1995).
Decisional conflict is a state of “uncertainty about which course of action to take” (O'Connor &
O'Brien-Pallas, 1989, p. 573), which is “more likely when a person is confronted with decisions
involving risk or uncertainty of outcomes, when high-stakes choices with significant potential
gains or losses are entertained, when there is a need to make value tradeoffs in selecting a course
of action, or when anticipated regret over the positive aspects of rejected options is probable”
(O’Connor, 2010, p. 2). Decisional conflict is manifested by verbalization of distress resulting
from “uncertainty about choices, verbalization of undesired consequences of alternative actions,
vacillation between choices, and delay in decision making” (O'Connor, 2010, p. 2).
Decisional conflict occurs as a consequence of inherently difficult decisions; however,
several modifiable cognitive, affective, and social factors can exacerbate the perceived
uncertainty. Uncertainty in decision making is “greater when a person: (a) feels uninformed
about the alternatives, benefits and risks; (b) is unclear about personal values; or (c) feels
unsupported in making a choice or pressured to choose a course of action” (O'Connor, 2010, p.
2). The ODSF asserts that decisional conflict can be lowered with decision-supporting
interventions, such as providing information about options, benefits, risks, and side effects;
helping to clarify values; and guiding through the steps of deliberation and shared decision
making. The ODSF not only includes decisional conflict, but also operationalizes it with the
Decisional Conflict Scale (DCS) (O'Connor, 1995).
Difficult decisions are frequently made by cancer patients. In a study of 100 patientphysician encounters concerning adjuvant breast cancer treatment, Siminoff, Fetting, and
Abeloff (1989) found that (a) the study encounter was the initial meeting with a medical
oncologist about adjuvant therapy for 79% of the patients, (b) only 38% of patients reported
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having any other important source of treatment/disease information, (c) 82% of patients had
made treatment decisions by the end of the meeting, (d) only 20% of patients had a prepared list
of questions, and (e) 85% of patients were informed about more than one treatment. During the
consultations, prognosis was discussed 83% of the time (90.4% physician-initiated, 9.6% patientinitiated); impact of treatment on lifestyle 63% of the time (50.8% physician-initiated, 49.2%
patient-initiated); risks of treatment 90.1% of the time (72.1% physician-initiated, 28% patientinitiated); benefits of recommended treatment 91.8% of the time (96.6% physician-initiated,
3.4% patient-initiated); patient emotional state 46% of the time (43.5% physician-initiated,
56.5% patient-initiated); and patient economic situation 18% of the time (44.5% physicianinitiated, 55.5% patient-initiated).
In addition to the descriptive data, Siminoff et al. (1989) found that patients and
physicians concurred on the risk of recurrence without treatment (p < .01), but not on the risk
with adjuvant treatment. In fact, 60% of patients overestimated their chances of cure with
adjuvant therapy by 20% or more compared with their physicians. Furthermore, little agreement
was exhibited about treatment risks (hair loss, nausea and vomiting, infection, bleeding, heart
damage, premature menopause, weight gain, infertility, pain, mouth sores, diarrhea), with only
weight gain demonstrating a modest level of agreement (K = .408). This study underscores the
importance of communication about the diagnosis of cancer, treatment recommendations, and
the risks and benefits of cancer treatment. As this was a descriptive study, the study design did
not allow for controlling of factors such as the amount or type of information that was conveyed
to the patients. This design flaw could have contributed to the level of disagreement. Some
other limitations of this study include the sample being entirely female and the participation of
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16 physicians of varying experience (seven full- or part-time medical oncology faculty and nine
first-year medical oncology fellows) in the study encounters.
Decisional conflict (measured by the DCS) was tested in a cancer clinical context with
two subsamples of patients: those with metastatic cancer who were deciding whether or not to
start palliative chemotherapy (N = 29) and women with early stage breast cancer who had to
choose between mastectomy and lumpectomy followed by radiation therapy (N = 141) (Koedoot
et al., 2001). Although the purpose of this study was to investigate the psychometric properties
of a Dutch translation of the DCS, there was decisional conflict identified, particularly in the
uncertainty subscale. The psychometric properties of the DCS were only partially confirmed in
Dutch cancer patients. In the palliative chemotherapy sample, the magnitude of the relationships
between the uncertainty subscale and each of the other two subscales was moderate (r > 0.50, p <
0.01); whereas in the surgical sample, the uncertainty subscale was not substantially related to
the other subscales (r < 0.20).
Decisional conflict was evaluated in a study of 82 early gastric cancer patients (mean age
= 62 years) who were asked to decide between endoscopic resection and surgical gastrectomy
(Lee et al., 2012). As compared to the group who chose surgical gastrectomy, those who chose
the more conservative endoscopic approach were younger (p = 0.038) and had fewer
comorbidities (p = 0.045). Overall decisional conflict scores were high, but significantly lower
(p = 0.016) in the group with a preference for endoscopic resection.
In a study by Flynn et al. (2008), decisional conflict was compared in adults with
advanced cancer who had accepted or declined participation in phase I cancer clinical trials. The
patients were classified as either accepters (n = 250) or decliners (n = 65) of a phase I trial.
Decisional conflict was measured using the DCS (Version A). Decliners had higher overall
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decisional conflict scores than accepters, with an effect size of 0.46 (95% CI, 0.18-0.74).
Although patients who chose to participate in a phase I study experienced less decisional conflict
than patients who declined to participate, the results of this study must be interpreted cautiously.
One limitation of this study is that it is not known if the informed consent process contributed to
the differences in decisional conflict. Additionally, recall bias may have been an issue since
decisional conflict was reported after the decision had been made.
Decisional conflict, as measured by the DCS, has also been used in older patients who are
deciding whether or not to undergo colorectal cancer screening. In their two-phase study of 46
patients aged 75 and older, Lewis et al. (2010) developed a decision aid using cognitive
interviewing techniques, then tested the effect of the decision aid on several decision making
outcomes, including decisional conflict. For the testing phase, the researchers utilized a prepost-test design. They found that decisional conflict decreased significantly (p < 0.01) after use
of a decision aid that included both an educational component and a values clarification exercise.
Although this study was limited by its lack of a control group and small sample size, it
demonstrates the usability of the DCS in older adults.
2.2

Decision Making
2.2.1 Role in decision making
Several researchers have investigated the desired and perceived roles in decision making.

Degner and Sloan (1992) developed a tool to measure role preferences related to decisionmaking. The tool consisted of two sets of five cards each: one for the patient/physician
dimension and one for the family/physician dimension. In the patient/physician card set, the five
cards illustrated roles that the patient and physician could assume, ranging from the patient
selecting his own treatment through a collaborative model to a scenario where the physician
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alone made the decision. Subjects were presented with the cards and allowed to compare each
card with every other card in subsets of two until their entire preference order across the set of
five cards was unfolded. Symptom distress was also measured. The sample consisted of 436
newly diagnosed cancer patients and 482 members of the general population. Only 12% of the
cancer patients preferred an active role, as compared with 64% of the general population. One
explanation for this marked difference could be the psychological impact of the cancer diagnosis
on decision making preferences. Neither symptom distress levels nor stage of disease were
related to patients’ role preferences. Univariate analysis revealed that three variables were
related to preferences about decision making: age, education, and gender. Age was correlated
with role preference in both the cancer and non-cancer patients, with older patients preferring
less control (p = 0.000). There were differences in role preferences by educational level, with
more highly educated subjects preferring more control (p = 0.000). Additionally, there was a
trend for women to prefer more decisional control (p = 0.034). Logistic regression revealed that
age was the most important predictor of decision-making preferences in both cancer and noncancer patients (r = 0.15, p = 0.000 and r = 0.11, p = 0.006, respectively), with older cancer and
non-cancer subjects preferring less control.
Barry and Henderson (1996) conducted a pilot study to explore the degree to which
terminal cancer patients desired participation in treatment-related decision making and to
determine whether these patients perceived they were achieving their desired level of
participation. The participants (n = 7) in the study ranged in age from 18-64 years (mean age, 47
years) and all had a diagnosis of cancer. They were interviewed a minimum of five times over
the course of their participation. When asked about role preferences in decision making,
participants chose from the following categories on a continuum: active, active-with-input,
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collaborative, passive-with-input, or passive. In the first interview, the desired form of decision
making was mostly collaborative or passive-with-input and patients were satisfied with that level
of involvement. With disease progression, however, patients desired more input as evidenced by
their rating of active or active-with-input. As desire for more participation in decision making
increased, participants perceived a greater discrepancy between the role they had and the role
they desired. Although the sample was very small, this study demonstrated that patients do have
a desire for participation in decision making, which may increase with disease progression.
In their study of 192 cancer patients receiving chemotherapy and/or radiation therapy,
Stacey, Paquet, and Samant (2010) sought to describe the extent to which cancer patients
perceived they are involved in making treatment decisions and the factors that influenced patient
involvement. Modified versions of Degner, Sloan, and Venkatesh’s Control Preferences Scale
(as cited in Stacey, et al., 2010, p. 88), the DCS, and the Preparation for Decision Making scale
by Bennett et al. (as cited in Stacey, et al., 2010, p. 88) were used. Approximately half of the
patients surveyed thought that they were offered choices for their cancer treatment. Compared
with patients who perceived that they were not offered choices, patients who perceived they were
offered choices indicated that they were more actively involved (55% versus 44%, p < 0.001),
were more likely to share in decision making (41% versus 26%, p < 0.001), and were less likely
to defer the decision to their physician (4% versus 29%, p < 0.001). Decisional conflict scores
were similar in participants offered and not offered choices. Of those patients offered choices,
100% were satisfied with their level of involvement in decision making, as compared with 94.5%
(p < 0.03) of the patients that were not offered choices. A major limitation of this study is that it
is not known whether the patients who perceived that they were not offered choices were
actually offered choices.
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2.2.2 Factors that influence decision making
The literature reveals that decision making may be influenced by several factors
including age, personality traits, past experiences, and family involvement. Chen, Haley,
Robinson, and Schonwetter (2003) conducted a study of 234 patients (173 hospice, 61 nonhospice) with a diagnosis of advanced lung, breast, prostate or colon cancer who had a life
expectancy of less than one year. The purpose of this study was to identify factors that may
influence the decision of whether to enter a hospice program or to continue with a traditional
hospital approach. The average age for hospice patients was significantly older than non-hospice
patients (69.2 versus 65, p = 0.009). Hospice patients had significantly more comorbidities (p =
0.035) and less independence in activities of daily living (p = 0.030) than hospital patients. Over
57% of the hospice sample reported that healthcare providers first told them about hospice
services. Subsequently, the final decision to enroll in a hospice program was described as being
made by families in more than 41% of case, followed by patients themselves (27.7%) and
physicians (26.6%).
There are many factors that are considered when patients make decisions about whether
to accept or decline physicians’ treatment recommendations. In a sample of 100 women with
breast cancer, Siminoff and Fetting (1991) found that 80% of the patients accepted their
physician’s primary treatment recommendation regarding adjuvant chemotherapy. Using
discriminant function analysis, the researchers found that 11 variables made a significant
contribution to the discrimination between the acceptors and non-acceptors of the treatment
recommendation. These factors related to: (a) the amount and specificity of information about
treatments conveyed to the patients, (b) the patient’s perceived strength of the treatment
recommendation itself, and (c) patient attributes such as education and willingness to take risks.
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Patients who declined treatment recommendation rated their physicians’ treatment
recommendation as less strong than other physicians’, were better educated, and were more
likely to be risk takers (p < 0.05).
Kelly-Powell (1997) used a grounded theory approach to explore the decision-making
experiences of adults with potentially life-threatening medical condition. The sample of 18
participants had diagnoses of heart disease, cancer, or renal failure; the mean age was 60 years,
with a range from 26 to 81 years. Personalizing choices was the core variable identified
following analyses of the interviews. The choices that respondents made were congruous with
their views of themselves within the context of their lives; decisions were grounded in feelings of
faith, trust, love, support, values, and beliefs that arose from each individual’s life and his or her
relationships with others. In making treatment decisions, past experiences were interpreted and
applied to their present situation. There were three major ways in which the past was
interpreted: integrating family and cultural history; incorporating past personal experiences; and,
adopting the experiences of others. When a particular treatment option did not correspond with
the interpretation of past experiences, the treatment was rejected or reservations about its
effectiveness were expressed. These findings are important because they highlight the focus on
the personal self, as opposed to the treatment, when making treatment decisions.
Petrisek, Laliberte, Allen, and Mor (1997) used retrospective analysis to determine if the
treatment decision-making process varied with patient age. The sample consisted of 179 women
with breast cancer: approximately 25% of these women were less than 50 years of age, 51%
were aged 50 to 69 years, and 24% were 70 years and older. The results of bivariate analyses
indicated that older women (70 years and older) were significantly more likely to be satisfied by
knowing only what the physician told them, while younger women wanted as much information
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as possible when choosing among treatment options (p < 0.001). The age 70 and older cohort
also reported being less confident than younger patients concerning their ability to be assertive in
treatment discussions with physicians. Patients in this age group were least likely to rate
themselves as excellent or good at telling physicians their wishes (p < 0.05); to get physicians to
adjust treatment plans to meet their needs (p > 0.05); and to be satisfied with their participation
in treatment decisions (p < 0.05). However, when asked about ways to facilitate treatment
decision making, they were significantly more likely to have desired that someone else make the
decision for them (p < 0.05).
2.2.3 Process of decision making
There have been several qualitative studies that have explored the process by which
patients make decisions. Gauthier and Swigart (2003) used a grounded theory approach to
determine the decision-making process used by terminally ill adults, as well as the factors that
influenced decision making. The 14 participants had a mean age of 72 (range 55 to 90 years)
and all were enrolled in hospice. Analysis of the interviews affirmed that decision making in the
context of a terminal illness comprises a complex process of interactive events rather than a
discrete behavior. Three major phases emerged from the interviews: (a) realizing terminality, (b)
accommodating living, and (c) engaging uncertainty; all of which supported the core process of
decision making. In this theoretical model, physical symptoms, pain, and decreasing physical
functioning influence key aspects of the decision-making process.
Another grounded theory study (Kohara & Inoue, 2010) explored the decision-making
process of 25 patients considering participation in phase I cancer clinical trials. More than 50%
of the patients were aged 60 and over, and the median age was 60 years (range 32 to 75 years).
Of the 25 participants, 21 agreed to participate in a phase I clinical trial and four declined. The
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core process identified in this study was searching for a way to live to the end. The four phases
that emerged from the data were: (a) only waiting for death to come if nothing is done; (b)
assessing the value of phase I trials; and, (c) finding decisive factors, and (d) reminding oneself
that this is the right decision. Four key factors influenced the decision-making process: (a)
patients’ perceptions of physicians’ explanations of the phase I trial; (b) patients’ perceptions of
their families’ attitudes toward the trial; (c) patients’ experiences with past anticancer therapies;
and, (d) patients’ attitudes toward living with cancer. This study highlights the detailed, multifactorial process of decision making in patients considering participation in cancer phase I
clinical trials.
Fraenkel and McGraw (2007) sought to conceptualize how patients participate in
decisions related to their health care. The following themes about medical decision making
emerged from semi-structured interviews of 26 participants: (a) it is often an ongoing process;
(b) it involves an extended social context; (c) it includes decisions distinct from those
traditionally studied; (d) it occurs in response to physicians’ recommendations; and, (e) it occurs
in the context of patients’ illness perceptions. Even though the participants in this study were not
terminally ill, the results are important for several reasons. Several previous studies measure
preference for decision-making participation at discrete time points, however this study
highlights this participation as an ongoing process. Additionally, whereas physicians focus on a
disease model that centers on symptoms, testing, diagnosis, and treatment, patients’ illness
perceptions center on how they interpret and cope with the effect of their symptoms on their
quality of life.
In a qualitative exploratory study, major influences on treatment preferences were elicited
from seriously ill older adults (Fried & Bradley, 2003). Twenty-three patients (mean age of 70)
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with life-limiting congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD), or cancer took part in in-depth semistructured interviews and focus groups. The major
influences that emerged as patients discussed how they made treatment decisions included
treatment burden, treatment outcome, and the likelihood of the outcome. Generally, if the
outcome of the treatment was favorable, patients expressed a greater willingness to accept its
burdens. This study highlights the importance of treatment burden in relation to treatment
outcome in older adults with serious illness, including cancer. However, since this was a small
qualitative study, the results can only generate hypotheses, not confirm them.
2.3

Comorbidity
Treatment of cancer in older adults is often complicated by concurrent management of

comorbid conditions. Changes in older adults’ organ systems occur because of a gradual
diminution in the physiologic reserve or functional capacity over time, resulting in the potential
for a multitude of acute and/or chronic conditions. It is important to be aware of the interplay
between these physiologic changes and cancer and its treatment. Age-associated changes
negatively impact the ability of older patients with cancer to tolerate stress and increase the risk
of toxicity from cancer therapy (Sawhney, Sehl, & Naeim, 2005; Sehl, Sawhney, & Naeim,
2005). The challenge in evaluating the literature that pertains to comorbid illness in older adults
with cancer is that there is no standard measure of comorbidity burden (Extermann, Overcash,
Lyman, Parr, & Balducci, 1998). As a result, identification of comorbid illness is often
interspersed with functional limitations and geriatric syndromes (Koroukian, 2009).
Arnoldi, Dieli, Mangia, Minetti, and Labianca (2007) categorized geriatric oncology
patients as frail, borderline, or non-frail. Among other things, the number of comorbidities
unrelated to the tumor was used for the classification in the following manner: frail (≥ 3
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comorbidities), borderline (multiple comorbidities not affecting performance status or daily
activities), and non-frail (no comorbidities). Applying this criteria to 153 patients with a mean
age of 76 (range 70-91); the researchers identified 14 frail, 30 borderline, and 109 non-frail
patients. Interestingly, the mean age for each of these subgroups was similar, the frail mean age
was 75 (range 70-91), the borderline mean age was 76 (range 70-83), and the non-frail mean age
was 76 (range 70-89). There was a significant difference in mortality at six months between the
frail and non-frail (50% versus 23%, respectively, p < .05) patients, but no difference was
observed between the other subgroups.
In a large Veterans Health Administration (VA) cross-sectional study (Zeber et al.,
2008), a secondary data analysis examined elderly veterans diagnosed with lung, colorectal,
prostate, and head and neck cancer (n=194,797). Receipt of various treatment modalities
including surgery, chemotherapy, and radiation therapy, was compared by age group, 70-84
versus 85-115. Seventy-percent of all cohort patients had hypertension, over half had
hyperlipidemia, heart disease (congestive heart failure, coronary artery disease, myocardial
infarction, atrial fibrillation) affected 40%, 25% had a diabetes diagnosis, and nearly 17% met
criteria for frailty. The prevalence of heart disease and frailty were greater among the older
group. Significant differences (p < .05) in treatment modality for each cancer type were also
found between the two age groups, with surgery (1.3% versus 0.6%), chemotherapy (2.1%
versus 0.8%), and radiation (1.7% versus 0.7%) all being more common among the younger
group. Differences in treatment rates by age group were sharper for certain kinds of cancer, such
as chemotherapy for lung cancer (9.0% versus 2.9%, p < .01) and head and neck cancer (4.6
versus 1.3%, p < .01), or surgery for colorectal cancer (5.8% versus 3.4%, p < .01). This study
demonstrates high rates of comorbid illness and extremely low treatment rates. This finding is
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likely influenced by the restriction to VA patients who, when compared to their non-VA
counterparts, are generally poorer, sicker, and predominantly male (Zeber et al., 2008). This was
merely a descriptive study, however, and the data cannot be used to draw conclusions about the
possible predictive nature of comorbid illness and the likelihood of receiving cancer treatment.
In a retrospective study, Koroukian (2009) utilized data from the Ohio Cancer Incidence
Surveillance System, Medicare claims and enrollment files, and the home health care Outcome
and Assessment Information Set to evaluate a cohort of older patients diagnosed with colorectal
cancer and receiving home health care. Identification of comorbid conditions was based on
guidelines of the National Cancer Institute, National Institute on Aging and functional limitations
were defined as needing assistance in activities of daily living (ADL). In this cohort of 957
patients with a mean age of 77.6 years, nearly 89% underwent colon resection and 36% received
chemotherapy. Patients with two or more comorbid conditions and those presenting with
limitations in two or more ADLs were 35% to 40% less likely to receive chemotherapy than their
healthier counterparts. Interestingly, the presence of two or more comorbid conditions was
associated with favorable disease-specific survival, but only at borderline statistical significance
levels [adjusted hazard ratio (AHR) = 0.77, 95% confidence interval (CI) = 0.60-1.00]. Presence
of comorbid conditions was not associated with overall survival. A limitation of this study is
that comorbidities, functional limitations, and geriatric syndromes are analyzed simultaneously,
thus the specific role of comorbidities cannot be evaluated. Furthermore, the outcomes of
surgery and chemotherapy were dichotomous (yes/no), so it is not known if there were any
adjustments to treatment as a result of the variables.
Girre et al. (2008) described modifications of the cancer treatment plan following a
geriatric oncology consultation in a cross-sectional pilot study. In this French study of 105
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cancer patients, the mean age was 79 years (range 70-97 years) and the majority (60.9%) had
breast cancer. More than half (60%) of these patients had not received any specific cancer
treatment at the time of their visit, 51.4% presented with progressive disease, and 57% had
metastatic disease. Comorbidity and seven other domains were assessed during the consultation,
including functional status, nutrition, mood, mobility, medication, social support, and residential
status. One-third of the patients had more than two comorbidities; the most frequent was high
blood pressure (47% of patients). Depression was suspected in 53.1% of the patients, as
evidenced by a score of greater than or equal to one on the mini-Geriatric Depression Scale
(GDS). In 38.7 % of cases, the treatment plan was modified after the geriatric oncology
consultation. Although there was no significant correlation between comorbidity and
modification of the treatment plan, this study is important because it highlights the prevalence of
comorbidity in this population. The generalizability of the data in this study is limited by the
predominance of breast cancer as the cancer diagnosis and the female sex (83%). Depression is
analyzed separately in this study; however, it is frequently considered a comorbid illness in this
population.
Although comorbidity often coexists with functional impairment in older adults with
cancer, they are actually distinct variables. In their study of 203 cancer patients, Extermann,
Overcash, Lyman, Parr, and Balducci (1998) compared the performance of two comorbidity
scales with three measures of functional status. Charlson, Pompei, Ales, and MacKenzie’s
Charlson Comorbidity Index (CCI) (as cited in Extermann et al., 1998, p. 1582) and Miller et
al.’s Cumulative Illness Rating Scale-Geriatric (CIRS-G) (as cited in Extermann et al., 1998, p.
1582) were the comorbidity scales used; the measures of functional status included Zubrod et
al.’s Eastern Cooperative Oncology Group (ECOG) performance status (PS) score (as cited in
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Extermann et al., 1998, p. 1582), Katz et al.’s ADL scale (as cited in Extermann et al., 1998, p.
1582), and Lawton and Brody’s Instrumental Activities of Daily Living (IADL) scale (as cited in
Extermann et al., 1998, p. 1582). The median age of patients was 75 years. The prevalence of
comorbidity was markedly varied by the scale used: 36% when rated with the CCI and 94%
when the CIRS-G was used. Functional assessment showed a large number of patients with mild
or moderate functional impairment, with 78.8% independent in ADL, 43.8% independent in
IADL, and 30.5% having an ECOG PS of zero. The correlation between the CCI and the CIRSG was moderate (r = 0.39, 95% CI, 0.26 to 0.50) for the CIRS-G total score. The functional
scales were strongly correlated: 0.51 (95% CI, 0.40 to 0.59) between ECOG performance status
and ADL, and 0.61 (95% CI, 0.52 to 0.69) between ECOG performance status and IADL. There
was low or no correlation between comorbidity and functional status across the measures. This
study demonstrates that comorbidity and functional status are poorly correlated in older cancer
patients.
2.4

Quality of Life (QOL)
QOL is subjective and multidimensional in nature (Cella, 1992). The assessment of QOL

has become a central concept in cancer clinical research and clinical practice (Varricchio, 2006).
Additionally, consideration of QOL has been identified as an important outcome in the care of
older adults with cancer (Oncology Nursing Society and Geriatric Oncology Consortium, 2007).
Michelson, Bolund, Bilsson, and Brandberg (2000) found overall QOL to be impaired in
older patients. Using the European Organization for Research and Treatment of Cancer Quality
of Life Questionnaire (EORTC QLQ-C30) (Aaronson et al., 1993), they surveyed a random
sample of the Swedish population aged 18-79 years. The oldest respondents (70-79 years)
scored significantly lower for global QOL, as well as for the scales of physical function, role
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function, and cognitive function. This group was also more symptomatic for fatigue and pain.
Interestingly, when compared to younger respondents in the 18-49 age bracket, women and men
in the two oldest age groups (60-69, 70-79 years) scored significantly (p < 0.001) higher for
emotional functioning.
In their study of 1,429 cancer patients, van den Beuken-van Everdingen et al. (2009)
measured the prevalence of non-pain symptoms and QOL. Patients were classified according to
tumor type and treatment status (curative treatment > 6 months ago, curative treatment ≤ 6
months ago, palliative antitumor treatment, or treatment no longer feasible). QOL and non-pain
symptoms were measured using the EORTC-C30 version 3 (Aaronson et al., 1993). Linear
regression analysis with demographic and disease-specific variables (type of cancer and
treatment status group) showed that the patients in either curative treatment group had
significantly better QOL than the patients in the palliative treatment group (p < 0.001). Patients
for whom treatment was no longer feasible had significantly poorer QOL than the patients
receiving palliative treatment (p < 0.001). When correlated with QOL, the physical and
psychological symptoms of fatigue (β = - 0.261, CI = - 0.31 to – 0.21, p < 0.001), pain (β = 0.155, CI = - 0.19 to – 0.12, p < 0.001), loss of appetite (β = - 0.082, CI = - 0.13 to – 0.04, p <
0.001), and constipation (β = - 0.36, CI = - 0.07 to – 0.00, p = 0.05) had significantly negative
effects on QOL. Patients with anxiety (β = 6.721, CI = 3.37 to 10.07, p < 0.001), and depression
(β = 11.067, CI = 7.53 to 14.61, p < 0.001) had significantly poorer QOL. Although this study
did not exclusively recruit older adults, the majority of the patients were between 60 and 80
years of age.
Esbensen, Osterlind, and Hallberg (2006; 2007) conducted a prospective study of older
patients (age 65 and older) with cancer to investigate possible changes in QOL in relation to age,
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contact with the health care system, ADLs, hope, social network, and support. The investigation
points were at time of diagnosis (baseline) and, again, at 3 months and 6 months after the
diagnosis. At 3-month follow-up (Esbensen et al., 2006), there was no significant change in
QOL score from baseline measurement; however, 16% of the sample did not participate at the 3month point. Those who did not participate at the 3-month follow-up had significantly lower
scores (p = 0.007) in global QOL than those that did continue in the study. Again, at 6-month
follow-up (Esbensen et al., 2007), there was no significant difference in global QOL. Attrition
continued to be a problem, with 25% of the original sample lost to follow-up at 6 months. As
was found at the 3-month point, those not participating at the 6-month point had significantly
lower (p = 0.018) global QOL at baseline than those who continued in the study. At 6-month
follow-up, there was an increase in emotional function (p = 0.009), which may account for
overall stability of QOL.
Only one study (Diefenbach, Mohamed, Horwitz, & Pollack, 2008) was found that
examined the associations among QOL, decision making, age, and other factors in cancer
patients. In this study of 391 patients with prostate cancer who underwent external beam
radiation, patients were divided, by age, into two groups: age ≤ 68 years and age > 68 years.
QOL was measured using Esper et al.’s Functional Assessment of Cancer Therapy Scale Prostate
Module (FACT-P) (as cited in Diefenbach et al., 2008, p. 149), which includes subscales for
physical wellbeing, emotional wellbeing, social/family wellbeing, and functional wellbeing. The
aspect of decision making that was assessed was the regret of prostate cancer treatment
decisions, using Brehaut et al.’s Decision Regret Scale (as cited in Diefenbach et al., 2008, p.
149). In both groups, psychological distress (r = -0.15 to - 0.50), worries about cancer
recurrence (r = - 0.11 to -0.46), and decisional regret (r = - 0.14 to – 0.32) were significantly and
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negatively correlated with the four subscales of QOL (p < .01). Although this study suggests a
relationship between decision making and QOL in adults with cancer, some of the limitations of
generalizing the results include a sample that was restricted to cancer type and treatment type.
2.5

Gaps in the Literature
One study (Diefenbach et al., 2008) addressed QOL and decision making in patients with

cancer. As previously stated, that study suggested a relationship between decisional regret and
QOL in cancer patients. There are multiple limitations to this study, one of which is the inclusion
of only patients with one type of cancer receiving one type of treatment. Although decisional
conflict, not decisional regret, is the variable being measured in the proposed study, the study by
Diefenbach et al. provides evidence of an association between QOL and decision making in
cancer patients. Although physical symptoms are measured using the physical subscale of the
FACT-P, there is no specific attention to comorbid medical conditions.
The study by Stacey et al. (2010), which was previously presented, aimed to demonstrate
the extent to which cancer patients perceived they were involved in making treatment-related
decisions. Although the study by Stacey et al. has some similarities to the proposed study,
namely the use of the ODSF as the guiding framework and use of the DCS as a measure of
decisional conflict, there are several important differences. First, the purpose of the study was
primarily that of evaluating involvement in decision making. The DCS was one of several tools
used to survey cancer patients about perceived and preferred roles in decision making. Second,
although there were older adults included in the study, the majority of the sample was younger
adults. Finally, neither comorbidity nor QOL were measured in the study by Stacey et al.
2.6

Summary of the Literature
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In summary, the literature supports the notion that decision making in the context of
serious illness can be exceedingly complex. As proposed in the ODSF, decisional needs,
decision quality, and decision support all influence decision making. Changes in a variety of
physiologic, functional, and psychosocial factors are known to characterize older adults with
cancer when compared to younger adults with cancer. Additionally, comorbidity is a frequent
and potentially therapeutically limiting problem in older cancer patients. Furthermore, the
literature demonstrated that physical, functional, psychological, and social changes influence
QOL and the decision-making process.
In this review of the literature, there were no studies found to date that addressed
decisional conflict, QOL, and comorbidity in older adults with cancer. The current study is an
attempt to fill this gap in the literature.

30

CHAPTER 3
METHODOLOGY
In this chapter, an overview of the study design, setting, and sample is discussed.
Additionally, the instruments that were used in this study are discussed in detail. Finally, the
procedures for data collection, protection of human subjects, and data analysis are reviewed.
3.1

Design
The study utilized a cross-sectional, descriptive, correlational study design to explore the

relationships between and among treatment-related decisional conflict, comorbidity, and quality
of life in older adults with cancer. A survey method was employed. The purpose of a survey
design is to generalize from a sample to a population so that inferences can be made about some
characteristic, attitude, or behavior of this population (Babbie, 1990).
3.2

Setting
The setting for recruitment of participants for this study was outpatient medical oncology,

radiation oncology, and palliative care practices in southern New Jersey. The physicians, nurses,
and office staff were educated about the study prior to the start of recruitment.
3.3

Sample
. The criteria for inclusion in this study were: (a) 65 years of age or older, (b) English-

speaking, (c) ability to read English at an eighth grade level, (d) having a current cancer
diagnosis, and (e) receiving cancer treatment. A power analysis was conducted to determine the
appropriate sample size to conduct correlational statistics including regression analysis. Previous
research indicates that an effect size of 0.30-0.40 is meaningful (O’Connor, 2010). Using the
effect size as a guideline, a sample size range of 193 (d = 0.40) to 346 (d = 0.30) was calculated.
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Thus, a sample size of 193 was needed to achieve power of .80 using a two tailed test of
significance at .05. After consultation with a statistician, it was decided that a sample size of 200
should be sufficient as there will likely be greater statistical power (T. Victor, personal
communication, February 11, 2012).
3.4

Instruments
The participants were asked to complete four instruments including: (a) Decisional

Conflict Scale (DCS) (O'Connor, 1995), (b) Self-Administered Comorbidity Questionnaire
(SCQ) (Sangha et al., 2003), (c) European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC QLQ-C30) (Aaronson et al., 1993), and (d) an
investigator-developed Demographic Information Form (DIF).
3.4.1 Decisional conflict scale (DCS)
O’Connor (1995) developed the DCS to elicit “healthcare consumers’ uncertainty in
making a health-related decision, the factors contributing to the uncertainty, and health-care
consumers’ perceived effective decision making” (p. 25). The DCS was developed using items
derived from the construct of decisional conflict, such as uncertainty, selected factors
contributing to the uncertainty, and perception of effective decision making (O'Connor, 1995).
The first subscale to be developed was the uncertainty subscale. It initially consisted of a fiveitem summated rating scale. The internal-consistency coefficient of the five-item scale was
extremely high (0.94), so the items were reduced to three with any appreciable change in internal
consistency (0.92) (O'Connor, 1995). The next subscale to be developed was the effectivedecision-making subscale. The purpose of this subscale was to elicit the extent to which
consumers agreed that they made informed decisions that were consistent with personal values,
that the decisions would be implemented, and the consumers’ satisfaction with the decision made
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(O'Connor, 1995). The factors-contributing-to-uncertainty subscale was the last subscale to be
developed. The data in this subscale included “being informed about options, risks, and benefits,
and feeling clear about values and value tradeoffs in the decision” (O'Connor, 1995, p. 26).
Additionally, there are items “related to pressures from important others” (O'Connor, 1995, p.
26) in this subscale. The effective-decision-making subscale is only used in circumstances
where a decision has already been made; the uncertainty subscale and factors-contributing-touncertainty subscale can be used during deliberation or after a decision is made (O'Connor,
1995).
The DCS has met acceptable standards of reliability and validity. It was initially tested in
two decision-making contexts: breast cancer screening and influenza immunization (n = 909)
(O'Connor, 1995). The test-retest correlation coefficient was 0.81. Internal consistency was
high, with alpha coefficients ranging from 0.78 to 0.92 for the total scale and from 0.58 to 0.92
for the subscales. As the instrument developer expected, high decision uncertainty (uncertainty
subscale) was correlated with feeling less informed about options, risks, and benefits and being
unsure of values in making the decision (factors-contributing-to-uncertainty subscale) (r = 0.49 –
0.53) (O'Connor, 1995). Additionally, low decision uncertainty (uncertainty subscale) was
correlated with feeling that the individual respondent had made an informed decision consistent
with personal values and that he or she anticipated implementing the decision (effectivedecision-making subscale) (r = 0.46 – 0.58) (O'Connor, 1995). Furthermore, feeling informed
about options, risks, and benefits and being clear about personal values (factors-influencinguncertainty subscale) was associated with feeling that an effective decision had been made
(effective-decision-making subscale) (r = 0.48 – 0.66) (O'Connor, 1995). The DCS consistently
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discriminated significantly (p < 0.0002) between those who accepted/rejected and those who
delayed/were unsure of the invitation to be immunized/screened (O'Connor, 1995).
There are four versions of the DCS; however, the traditional DCS (O'Connor, 2010) was
used in this study (Appendix A) because it has been used in more than 30 studies and sufficient
psychometric data exist. The traditional DCS is a 16-item instrument that consists of five
subscales: informed (items 1-3); values clarity (items 4-6); support (items 7-9); uncertainty
(items 10-12); and effective decision (items 13-16). Items in each subscale are scored on a 5point Likert scale (0 = strongly agree, 1 = agree, 2 = neither agree nor disagree, 3 = disagree, and
4 = strongly disagree). In order to determine the total score, the scores of the 16 items are: (a)
summed, (b) divided by 16, and (c) multiplied by 25 (O'Connor, 2010). DCS scores range from
0 (no decisional conflict) to 100 (extremely high decisional conflict). Subscale scores are
calculated by adding the scores of the items for that subscale, dividing by the number of items in
the subscale, and multiplying by 25 (O'Connor, 2010). The traditional DCS has been adjusted to
an eighth-grade reading level and takes approximately five to ten minutes to complete
(O'Connor, 1995). Although the DCS is protected by copyright, it is freely available for use as
long as it is cited in any questionnaires or publications (O'Connor, 2010).
According to A. M. O’Connor (personal communication, June 14, 2012), the investigator
should “set the stage” for participants by asking them to focus on their opinions regarding a
treatment decision specific to the area of inquiry. Additionally, she stressed the importance of
knowing on which decision participants are focusing, as well as the time frame in which the
decision was made (A. M. O’Connor, personal communication, June 14, 2012). To this end, the
investigator developed a paragraph that focuses participants to cancer treatment-related
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decisions, an open-ended question to determine the decision that was made, and a multiplechoice question to determine when the decision was made.
3.4.2 Self-Administered Comorbidity Questionnaire (SCQ)
The SCQ (Katz, Chang, Sangha, Fossel, & Bates, 1996; Sangha et al., 2003) was
developed as a self-administered measure of comorbidity for clinical and health services research
settings. The SCQ was modeled on the Charlson Comorbidity Index (CCI), an extensively
validated chart review-based comorbidity instrument (Katz et al., 1996; Sangha et al., 2003).
Katz et al. developed the SCQ to address the limitation that measurement of comorbidity
required abstraction of medical records.
The SCQ was initially pilot tested on a small sample of older patients, and then was
administered to 170 patients aged 50 and older (mean 65.3 years). For each patient who
completed the SCQ, a CCI value was assigned by a research nurse who was blinded to the SCQ
data. The test-retest reliability of the questionnaire in 26 patients was 0.91 as measured with the
intraclass correlation coefficient (Katz et al., 1996). The Spearman correlation between the SCQ
and the CCI was 0.63 (p = 0.0001) (Katz et al., 1996).
Although the instrument developed by Katz et al. (1996) was a valid and reliable tool,
severity of illness was not assessed for each disease. Therefore, Sangha et al. (2003) revised the
tool to allow the participant to note the severity of each comorbid disease and their perception of
its impact on their function. This new version of the SCQ was studied in a sample of 170
patients over 50 years of age. The test-retest reliability for the SCQ in 26 patients was 0.94 (95%
CI 0.72, 0.99) as calculated by the intraclass correlation coefficient and 0.81 by the Spearman
correlation coefficient (Sangha et al., 2003). The correlation between the SCQ and the CCI was

35

moderately strong (r = 0.32 for the entire instruments and 0.55 for truncated versions of the
measures that contained only comparable items for each instrument) (Sangha et al., 2003).
In order to not only assess the presence of comorbidities but also their degree of severity,
the SCQ developed by Sangha et al. (2003) was used in this study. The SCQ is a 13-item
instrument with the option of adding three additional conditions in an open-ended fashion.
Thirteen medical conditions are listed, including: heart disease, high blood pressure, lung
disease, diabetes, ulcer or stomach disease, kidney disease, liver disease, anemia or other blood
disease, cancer, depression, osteoarthritis or degenerative arthritis, back pain, and rheumatoid
arthritis. Additionally, there is an item for “other medical problems” with instructions and space
to “please write in” (Sangha et al., 2003, p. 157). For each medical problem, the participant is
asked the following questions: “Do you have the problem?”, “Do you receive treatment for it?”,
and “Does it limit your activities?” (Sangha et al., 2003, p. 157). Responses to each question are
dichotomous and recorded by marking either yes or no. A maximum of three points can be
scored for each medical condition: one point for the presence of the medical problem, one point
if treatment is received for the medical problem, and one point if the medical problem causes a
limitation in functioning. The total number of points depends on whether or not the optional
open-ended items are used (Appendix B). The SCQ is short, easily understood, and can be
completed by individuals without any medical background in about 5 to 10 minutes (Sangha et
al., 2003). Permission to use the SCQ was obtained from the authors (Appendix C).
3.4.3 European Organization for Research and Treatment of Cancer (EORTC) Quality
of Life Questionnaire (QLQ-C30)
The EORTC QLQ-C30 (Aaronson et al., 1993) is an instrument that was developed to
assess QOL in cancer patients, as well as to assess changes in QOL throughout the cancer
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pathway and during or after a specific treatment regimen. The EORTC QLQ-C30 incorporates
five functional scales (physical, role, cognitive, emotional, and social); three symptom scales
(fatigue, pain, and nausea/vomiting); and global health and QOL scales. The remaining single
items address additional symptoms, such as dyspnea, loss of appetite, sleep disturbance,
constipation, and diarrhea, as well as the perceived financial impact of the disease and treatment.
Additionally, there are supplementary items for disease-specific modules, such as breast, lung,
head and neck, ovarian, gastric, and cervical cancer, as well as multiple myeloma.
Psychometric properties of the EORTC QLQ-C30 were evaluated in an international field
study that was conducted in 13 countries with 305 patients with nonresectable lung cancer
(Aaronson et al., 1993). The role functioning scale was the only multi-item scale that failed to
meet the minimal standards for reliability (Cronbach’s α ≥ 0.70) either before or after treatment.
All interscale correlations were significant, with the strongest correlations being both before and
during treatment between the physical functioning, role functioning, and fatigue scales (r = 0.540.63, p < .01). Substantial correlations (r > .40, p < .01) were also noted between the fatigue,
emotional, and social functioning scales. In general, the interscale correlations were moderate
indicating that, although related, they are assessing distinct components of the QOL construct
(Aaronson et al., 1993).
Version 3 of the EORTC QLQ-C30 (Appendix D) was used in this study as it is currently
the standard version and recommended to be used for all new studies (Fayers et al., 2001). The
EORTC QLQ-C30 (Version 3) is a 30-item instrument that consists of multi-item scales and
single-item measures, including five function scales, three symptom scales, global health
status/QOL scales, and six single items. The two global health status/QOL items are scored on a
7-point Likert scale (1 = very poor and 7 = excellent); the remaining 28 items are scored on a 4-
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point Likert scale (1 = not at all, 2 = a little, 3 = quite a bit, and 4 = very much). All of the scales
and single-item measures range in score from 0 to 100. A high scale score represents a higher
response level. Thus, “a high score for a functional scale represents a high/healthy level of
functioning, a high score for the global health status/QOL represents a high QOL, but a high
score for a symptom scale/item represents a high level of symptomatology/problems” (Fayers et
al., 2001, p. 6). The developers of the instrument provide the scoring procedure for statistical
packages. Permission to use this instrument was obtained by completing a registration process
through the EORTC website. Permission is granted when an email including the links for the
instrument and scoring guide is received (European Organization for Research and Treatment of
Cancer, 2011) (Appendix E).
3.4.4 Demographic Information Form (DIF)
The DIF, designed by the investigator, includes 17 items; five items are open-ended
requiring participants to fill in a blank and 12 items offer a list of choices (Appendix F). The
DIF was used to describe the population under study including age, gender, marital status, race,
religion, work status and education (items one through seven). Item eight is an open-ended
question that requires written responses to list all prescription and over-the-counter (OTC)
medications that subjects are taking. Items nine through 17 will be used in the evaluation of
cancer type, cancer treatment, and decision support.
3.5

Procedure for Data Collection
3.5.1 Pilot Study
A pilot study was conducted to evaluate the usability of the DCS in older adults with

cancer. Although the DCS has been tested extensively, the investigator developed instructions
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and questions to focus participants to cancer treatment-related decisions. Additionally, since
many older adults experience vision changes that can influence their ability to understand written
material (National Institute on Aging, 2012), readability of the paper instruments needed to be
established. The text of the DCS was altered to Times New Roman font with a 14-point type
size to enhance readability (National Institute on Aging, 2012). Since the surveys were going to
be anonymously completed without the investigator present, it was important to ascertain
whether or not the instructions were clear. Therefore, the pilot study objectives included:
1. To trial the understandability of the investigator-developed instructions for the DCS
in older adults with cancer
2. To trial the readability of the font size and font style of the paper survey
Approval from the Duquesne University Institutional Review Board (IRB) (Appendix G)
and permission from a palliative care practice were obtained prior to beginning the pilot study.
Participation in the pilot study was voluntary and all participants had the right to refuse. Written
consent (Appendix H) was obtained by the investigator from each participant for the pilot study.
All signed consents, completed surveys, and written comments were kept in a locked file cabinet
separate from other study materials. Consideration was given to the fact that all participants
were older adults that had cancer and that fatigue or emotional distress may occur. This was not
a time-limited study, nor was the amount of time needed to complete the survey measured, so
participants were able to complete the surveys at their leisure. Furthermore, participants were
notified that they could withdraw from the study at any time.
A convenience sample of participants who met the same inclusion criteria for the main
study was recruited. The office nurse identified potential participants and asked if they were
interested in participating in the pilot study. If they agreed, the nurse provided the name and
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phone number to the investigator. The investigator orally invited the individual by telephone to
participate in the study. The setting for the study was determined by the participant—either in an
outpatient office or in the participant’s home.
Once informed consent was obtained, participants were asked to complete the DCS in the
presence of the investigator. A think-aloud method, or usability testing methodology, was
utilized where subjects are encouraged to talk out loud and express their thoughts and questions
while they answer each item. The investigator listened and took notes while each subject
completed the DCS. Based on participant feedback, revisions were made to the instructions and
the open-ended question. Two participants then reviewed the revised instructions to ensure
clarity and agreement was obtained from both participants.
3.5.2 Main Study
After obtaining approval from the IRB of Duquesne University (Appendix I) and
permission from the individual practices, the investigator conducted inservice sessions with the
staff of three outpatient oncology practices (two medical oncology and one radiation oncology)
and one outpatient palliative care practice. A nursing representative in each office was identified
as a key person for assistance in identification of potential participants and communication
regarding the study. During the inservice sessions, the investigator reviewed the purpose of the
study, the recruitment process, and the contents of the survey packet with the office nurses. An
opportunity was provided to ask questions and the nurses were provided with contact
information for the investigator for future questions.
With the permission of the practices, flyers advertising the study were developed by the
investigator and placed in waiting rooms and exam rooms. Interested parties were directed to
contact any nurse in the practice. If patients who met the inclusion criteria were identified by
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nurses, a survey packet was offered to them. Once completed, the survey packet was returned to
the nurse, who stored it in a locked cabinet until retrieved by the researcher conducting the study.
The survey packets included: (a) an IRB approved cover letter that described the purpose
of the study and what was required of the participants (Appendix J), (b) the DCS, (c) the SCQ,
(d) the EORTC QLQ-C30 (version 3), (e) the DIF, and (f) a return envelope.
3.6

Procedure for Protection of Human Subjects
The investigator requested approval for conducting the study from the IRB of Duquesne

University, utilizing standard forms and procedures set forth by the committee. The investigator
provided an overview of the research questions, design, methods, and a sample packet of data
collection tools.
Participation in the study was voluntary, and all participants had the right to refuse.
Potential participants were informed that results will be reported in an aggregated format, with
no information identifying any individual. The only identification that was used was a numeric
code on the return envelopes and a corresponding numerical code on the survey instruments.
Participants were not known to the researcher. In addition, the cover letter indicated to the
potential participants that they should not include any contact or identifying information. The
cover letter in the survey packet indicated that by completing and submitting the completed
forms, the subject was consenting to participate. The cover letter provided a means for
individuals who had concerns about the study or wished to discuss issues a way to contact the
investigator. During the study, the investigator kept all of the returned instruments in a locked
file cabinet separate from any data.
Since all potential participants in this study are older and have cancer, it is possible that
fatigue may have occurred while completing the survey packets. Additionally, since potential
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participants were asked to reflect upon their cancer, treatment decisions and quality of life, it is
possible that emotional distress occurred. Potential participants were notified that participation
in this study was voluntary and that they could withdraw from the study at any time.
Furthermore, completion of the survey packets was not time-limited, so potential participants
could complete them at their leisure to minimize fatigue or emotional distress.
3.7

Procedure for Data Analysis
Upon receipt of each completed survey packet, the investigator entered the data onto an

Excel spreadsheet created by the investigator. For quality control, the investigator rechecked all
data entered for each participant. The data was then exported to SPSS 21.0 for data analysis.
The investigator used descriptive statistics, including means, standard deviations, ranges,
and percentages, to summarize demographic data and the major variables under study including
decisional conflict, comorbidity, and QOL. Correlational analysis was used to answer question
one: What is the relationship between and among treatment-related decisional conflict, QOL,
and comorbidity in older adults with cancer? There are several assumptions that must be met in
order to use parametric testing: (a) the variables are normally distributed, (b) there is a linear
relationship between the independent and dependent variable(s), and (c) there is
homoscedasticity (Osborne & Water, 2002). Histogram and scatter plots were generated to
visualize the data to test for the first two assumptions. The measures were not normally
distributed. Since there was a moderately positive skewness, an attempt to transform the data
was made by using the square root transformation method (Howell, 2007). Histograms and
scatterplots were regenerated, which continued to show that the data were not normally
distributed. The assumptions of parametric testing, therefore, were not met. Based on this
observation, Spearman's rank-order correlation (rs) was used to analyze these data. The
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Spearman correlation was used to measure the magnitude and direction of a relationship between
two variables (Gravetter & Wallnau, 2007; Polit, 2010). It is important to realize that these
methods of statistical analysis simply describe a relationship between two variables; Spearman’s
correlation cannot explain why two variables are related (Gravetter & Wallnau, 2007). The
correlation coefficient can range from -1.00 (a perfect negative relationship) to 1.00 (a perfect
positive relationship), with zero representing absolutely no relationship between the two
variables (De Muth, 2009). The strength of the relationship was interpreted as follows: a
correlation coefficient of 0.10 will represent a weak or small association, a correlation coefficient
of 0.30 will represent a moderate correlation, and a correlation coefficient of 0.50 or larger will
represent a strong or large correlation (Cohen, Cohen, West, & Aiken, 2003).
Regression analysis techniques were used to answer question two: To what degree does
the variability in QOL and level of comorbidity predict decisional conflict in decision making?
Regression is used to analyze relationships between variables and to make predictions about
values of variables (Maxwell, 2000). Since there were two independent variables that were
evaluated in this study, multiple regression analysis was the method utilized. Multiple linear
regression analysis allows the investigator to understand and predict a dependent variable on the
basis of two or more independent variables. There are several assumptions that must be met in
order to use multiple linear regression models for purposes of prediction, including: linearity of
the relationship between dependent and independent variable, independence of the errors,
homoscedasticity of the errors, and normality of the error distribution (Cohen et al., 2003.)
These assumptions were tested with scatterplots and all assumptions were met. The multiple
regression coefficient (R) represents the magnitude of the relationship between the dependent
variable and predictor variables, taken together (De Muth, 2009).
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CHAPTER 4
RESULTS

This chapter serves to present and discuss the results of the analyses conducted for this
study. Initially, a pilot study was conducted to ensure the usability of the Decisional Conflict
Scale (DCS) with older adults. A discussion of the pilot study outcomes begins this chapter. A
discussion of the main study follows, beginning with a series of descriptive statistics that were
conducted in order to present an initial picture of this sample of respondents as well as the data
set analyzed. Finally, a discussion of a series of reliability analyses, followed by a series of
regression analyses serving to test this study’s hypotheses, is presented.
4.1

Pilot Study
4.1.1 Pilot Study Description
Prior to proceeding with the main study, a pilot study was conducted. The purpose of the

pilot study was to evaluate the usability of the DCS in older adults with cancer. The objectives
of the pilot study were:
1. To trial the understandability of the investigator-developed instructions for the DCS
in older adults with cancer
2. To trial the readability of the font size and font style of the paper DCS survey.
The investigator met each participant in a mutually agreed upon place and at a mutually agreed
upon time. Before administering the survey, the investigator explained the purpose of the study
and obtained informed consent. Once informed consent was obtained, participants were asked to
complete the DCS in the presence of the investigator. A think-aloud method, or usability testing
methodology, was utilized where participants are encouraged to talk out loud and express their
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thoughts and questions while they answer each item (Aanstoos, 1983). The investigator listened
and took notes while each participant completed the survey. When appropriate, the investigator
answered or clarified questions or comments. Pilot study participants (N=6) met all study
inclusion criteria (Chapter 3.3). The sample was comprised of three male and three female
participants with a mean age of 74.83 years (Range = 65-88 years).
4.1.2 Pilot Study Results
After the pilot study was completed, all comments and questions were compiled in order
to identify repeated themes among participants. When reading the opening paragraph, one
participant (16.7%) commented that explaining that “pros are advantages and cons are
disadvantages” seemed “oversimplified.” When participants read the open-ended question, 83%
(n=5) verbalized the decision that they made about their cancer treatment but did not write the
decision on the lines provided, 67% (n=4) asked for clarification about the type of decision, and
50% (n=3) responded with more than one decision. All participants (n=6) reported that the font
style and font size was clear and easily readable.
Based on the participants’ feedback, several changes were made to the opening paragraph
and open-ended question. In the opening paragraph, the word “complex” was put in bold font.
Since most of the comments were related to the open-ended question, several changes were made
to improve clarity:
1. The sentence, “This decision may be related to surgery, chemotherapy, radiation
therapy, or other treatment” was removed from the opening paragraph and added to
the open-ended question.
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2. Participants are prompted to think about “one complex decision” related to their
cancer treatment. The word “one” was underlined and made bold for added
emphasis.
3. The verbiage was changed from “what was a decision that you made…” to “please
state what that complex decision was”.
No changes were made to the font size or font style.
Once the revisions were made, two of the participants then reviewed the revised opening
paragraph and open-ended question. Both participants agreed that the revisions enhanced clarity
and there were no further questions or comments suggesting a need for further revision. Both
objectives for the pilot study were met. Approval was then sought and received from the
Institutional Review Board (IRB) of Duquesne University for the main study (Appendix I).
4.2

Main Study Demographic Characteristics

Data were analyzed using IBM SPSS Statistics Version 21.0 (2012). Initially, a series of
descriptive statistics were conducted on these data in order to better describe this sample of
participants and the data analyzed. In an open-ended question, participants were asked to
identify a complex decision that they had made in regard to cancer treatment. Table 4.1
summarizes responses with respect to the type of complex decision. The majority of participants
identified their complex decision as related to chemotherapy. Fifty-nine percent of cases
consisted of chemotherapy, with close to 26% of cases consisting of radiation therapy. In total,
9% of cases consisted of surgery, with each of the remaining categories of response containing
2% or less of the sample. Other complex decisions included: (a) participation in clinical trial, (b)
choice of cancer doctor or facility, (c) whether to obtain a second opinion, and (d) stem cell
transplantation.
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Table 4.1
Type of Complex Decision Made Related to Cancer Treatment (N=200)
Response

n

%

Chemotherapy
118
59.0
Radiation therapy
51
25.5
Surgery
18
9.0
Clinical trial
4
2.0
Second opinion
4
2.0
Cancer doctor/facility
3
1.5
Stem cell transplant
1
.5
Missing
1
.5
Note. N = 200 reflects the total number of participants who initiated the survey. Not all items
were answered by all participants.
Using a multiple choice question, participants were asked to identify how long ago they
had made the decision that they identified. The following table (4.2) summarizes data on the
length of time since a decision was made. In 47% of cases (n=94), the length of time consisted of
fewer than three months, while the length of time was 3 to 6 months in close to 15% of cases
(n=29; 14.5%). Nineteen percent of participants (n=38) indicated that the decision had been
made over one year ago.
Table 4.2
Length of Time Since Decision Was Made (N=200)
Response

n

%

Fewer than 3 months
94
47.0
3 to 6 months
29
14.5
6 to 9 months
18
9.0
9 to 12 months
17
8.5
Over 1 year
38
19.0
Missing
4
2.0
Note. N = 200 reflects the total number of participants who initiated the survey. Not all items
were answered by all participants.
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The mean age of participants was 73.1 years (N = 200; SD = 7.0; Range = 65-92 years).
Table 4.3 summarizes additional demographic characteristics of the study sample. With respect
to gender, a slight majority of female participants (n = 102; 51%) was found within this sample.
Regarding marital status, slightly over 50% of participants were found to be married (n = 101;
50.5%), with slightly over 27% being widowed (n = 55; 27.5%). In total, 16% (n = 32) of
participants were found to be divorced, with 6% (n = 12) found to be single and having never
been married.
Three participants (1.5%) did not disclose their race. Almost 88% of participants were
found to be white (n = 175, 87.5%), with almost 6% being African-American (n = 11; 5.5%) and
almost 5% being Hispanic (n = 9; 4.5%). The remaining categories of response for race (Native
American/Eskimo and Asian) each consisted of 0.5% of the entire sample. A slight majority of
this sample identified themselves as Catholic (n = 105; 52.5%). Finally, nearly 72% of this
sample were found to be retired (n = 143).
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Table 4.3
Demographic Characteristics of Study Participants (N= 200)
Response

n

%

Gender
Female
Male

102
98

51.0
49.0

Marital status
Married
Widowed
Divorced
Single, never married

101
55
32
12

50.5
27.5
16.0
6.0

Race
White
African American
Hispanic
Asian
Native American/Eskimo
Missing

175
11
9
1
1
3

87.5
5.5
4.5
.5
.5
1.5

Religion
Catholic
Protestant
Other Christian
Jewish
None
Jehovah Witness
Missing

105
48
26
11
6
1
3

52.5
24.0
13.0
5.5
3.0
.5
1.5

Employment status
Retired
143
71.5
Disabled
32
16.0
Employed part-time
18
9.0
Employed full-time
3
1.5
Missing
4
2.0
Note. N = 200 reflects the total number of participants who initiated the survey. Not all items
were answered by all participants.

49

Additional descriptive analysis was conducted focusing upon the types of cancer that
participants had, with these data summarized in Table 4.4. Most commonly, 23% of participants
had lung cancer (n = 46), with 16% having leukemia, myelodysplastic syndrome (MDS), or
lymphoma (n = 32). Next, 12% of participants had breast cancer (n = 24) and close to 12% of
participants had colorectal cancer (n = 23; 11.5%). All remaining types of cancer each composed
less than 7% of the entire sample.
A slight majority of participants indicated that they had not been told that the cancer had
spread (n = 103; 51.5%). Regarding treatment, 87% (n = 174) stated that they had received
chemotherapy for their cancer. Additionally, a slight majority (n = 104; 52.0%) of participants
indicated that they had received radiation therapy, with 55% of participants (n = 110) indicating
that they have had surgery for cancer.
Over 40% of participants (n = 81; 40.5%) indicated that their spouse or significant other
accompanied them to appointments with their cancer doctor. Nearly twenty-six percent of
individuals (n = 51; 25.5%) stated that they were accompanied by their children. Nineteen
percent of participants (n = 38) stated that they went alone. Other participants were accompanied
to appointments by friends, other family members, or paid caregivers.
Participants were asked to identify resources, support people, or decision aids that were
helpful to them in making decisions about their cancer treatment. Participants were asked to
identify all possible sources of support. Cancer doctors were identified most often (n = 198;
99.0%), followed by family (n = 160, 80.0%), cancer nurses (n = 74; 37.0%), and websites (n =
32; 16.0%). Other sources of support included spiritual support person, books, support group,
family doctor, friends, hypnotist, nurse navigator, social worker, and therapist.
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Table 4.4
Cancer Characteristics of the Study Sample (N = 200)
Response

N

%

Type of cancer
Lung
Leukemia/myelodysplastic syndrome/lymphoma
Breast
Colorectal
Pancreas/gall bladder
Ovarian/uterine
Multiple myeloma
Head/neck
Prostate
Liver
Bladder
Melanoma
Kidney
Sarcoma
Missing

46
32
24
23
13
12
12
11
9
6
4
4
2
1
1

23.0
16.0
12.0
11.5
6.5
6.0
6.0
5.5
4.5
3.0
2.0
2.0
1.0
.5
.5

Has the cancer spread?
No
Yes

103
97

51.5
48.5

Have you ever received chemotherapy?
Yes
No

174
26

87.0
13.0

Have you ever received radiation therapy?
Yes
No
Missing

104
95
1

52.0
47.5
.5

Have you ever had surgery for cancer?
Yes
No
Missing

110
87
3

55.0
43.5
1.5

Who goes to cancer doctor appointments with you?
Spouse/significant other
Child
Alone

81
51
38

40.5
25.5
19.0
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Other family
Friend
Paid caregiver
Missing

19
4
3
4

9.5
2.0
1.5
2.0

Resources/support/decision aids
Cancer doctor
198
99.0
Family
160
80.0
Cancer nurse
74
37.0
Websites
32
16.0
Priest/minister/spiritual support
15
7.5
Support group
11
5.5
Books
8
4.0
Other
Family doctor
1
.5
Friends
5
2.5
Hypnotist
1
.5
Nurse navigator
1
.5
Social worker
1
.5
Therapist
2
1.0
Note. N = 200 reflects the total number of participants who initiated the survey. Not all items
were answered by all participants.
Additional descriptive analysis was conducted on the continuous measures of the highest
grade of school completed, the number of medications taken, and the year diagnosed. First, the
highest grade of school completed was found to have a mean of 13.1 years (SD = 2.1), with a
minimum of eighth grade and a maximum of 18 years of schooling. Number of prescription and
over-the-counter medications that participants were currently taking was found to have a mean of
6.4 (SD = 3.4) with a minimum of zero and a maximum of 22 medications. Finally, participants
were found to be diagnosed with cancer between 1988 and 2013. The mean year of diagnosis
was 2011 (SD = 3.5).
4.3

Descriptive Analysis of Independent and Dependent Variables
Descriptive analysis of the dependent variable, decisional conflict, and independent

variables, quality of life (QOL) and comorbidity were conducted. Table 4.5 summarizes the
results of the descriptive statistics conducted on the scale measures of the DCS, the European
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Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire
(QLQ-C30), and the Self-Administered Comorbidity Questionnaire (SCQ). A very minimal
amount of missing data was present with respect to these variables with measures of central
tendency and variability reported in Table 4.5.
4.3.1 Decisional Conflict
Overall, decisional conflict was found to have a mean DCS total score of 22.1 (SD =
12.5; Range = 0.0 - 70.3; scale Range = 0.0 - 100.0). Subscale four (uncertainty) had the highest
scores relative to the subscales, with a mean of 29.2 (SD = 18.2; Range = 0.0 – 100.0; scale
Range = 0.0 - 125.0).
4.3.2 Quality of Life
The mean score on the two global health status/QOL questions was 44.2 (SD=20.7;
Range=0.0 - 100.0; scale Range=0.0 - 100.0). Of the function scales, cognitive function had the
highest mean score (M = 80.1; SD = 18.8; Range = 16.7 -100.0; scale Range = 0.0 - 100.0),
while role function had the lowest (M = 59.8; SD = 28.6; Range = 0.0 -100.0; scale Range = 0.0 100.0). Fatigue had the highest mean of the symptom scales (M = 41.4; SD = 21.6; Range = 0.0
- 100.0; scale Range = 0.0 - 100.0). Specific to the six single items, dyspnea had the highest
mean of 28.3 (SD = 26.7; Range = 0.0 - 100.0; scale Range = 0.0 - 100.0).
Table 4.5
Descriptive Data Regarding Study Measures for Dependent and Independent Variables
Measure
DCS Total
DCS S1
DCS S2
DCS S3
DCS S4
DCS S5

N
198
200
199
200
200
199

Mean
22.1
21.7
19.9
19.1
29.2
21.0
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SD
12.5
15.7
13.7
12.0
18.2
13.5

Range
0.0 – 70.3
0.0 – 100.0
0.0 – 100.0
0.0 – 50.0
0.0 – 100.0
0.0 – 50.0

EORTC QLQ-C30
Global health status/QOL
Physical function
Role function
Emotional function
Cognitive function
Social function
Fatigue
Nausea/vomiting
Pain
Dyspnea
Insomnia
Appetite loss
Constipation
Diarrhea
Financial problems

200
200
200
200
200
200
200
200
200
200
200
200
200
200
198

44.2
64.1
59.8
79.0
80.1
68.3
41.4
11.3
30.6
28.3
26.5
25.5
23.2
12.3
22.7

20.7
23.9
28.6
20.0
18.8
25.3
21.6
17.7
25.2
26.7
27.2
26.5
29.6
21.5
28.2

0.0 – 100.0
0.0 – 100.0
0.0 – 100.0
8.3 – 100.0
16.7 – 100.0
0.0 – 100.0
0.0 – 100.0
0.0 – 83.3
0.0 – 100.0
0.0 – 100.0
0.0 – 100.0
0.0 – 100.0
0.0 – 100.0
0.0 – 100.0
0.0 – 100.0

SCQ
200
9.6
4.1
3.0 – 23.0
Note. DCS = Decisional Conflict Scale, which consists of a global score and five subscales: S1
= informed; S2 = values clarity; S3 = support, S4 = uncertainty, and S5 = effective decision.
EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire, which consists of a global score, five function scales (physical, role,
emotional, cognitive, and social), three symptom scales (fatigue, pain, and nausea/vomiting), and
six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact).
SCQ = Self-Administered Comorbidity Questionnaire. All values were rounded to the nearest
tenth decimal place.
4.3.3 Comorbidity
In measuring comorbidity, the mean score of the SCQ (Table 4.5) was 9.6 (SD = 4.1;
Range = 3.0 - 23.0; scale Range 0.0 - 48.0). Other than cancer (n = 198, 99%), the most reported
comorbid illness was high blood pressure (n = 142, 71%). Items 14 through 16 of the SCQ
provided subjects the opportunity to write in any medical conditions that they had that were not
included in the survey. The most common write-in response was high cholesterol (n = 17,
.09%). Data regarding the remainder of illnesses reported are presented in Table 4.6.
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Table 4.6
Descriptive data regarding types of comorbid illnesses identified in SCQ
Comorbid illness
N
%
Heart disease
46
23
High blood pressure
142
71
Lung disease
67
33.5
Diabetes
56
28
Ulcer or stomach disease
15
7.5
Kidney disease
9
4.5
Liver disease
23
11.5
Anemia or blood disease
45
22.5
Cancer
198
99
Depression
38
19
Osteoarthritis/degenerative
53
26.5
arthritis
Back pain
72
36
Rheumatoid arthritis
11
5.5
Write-in responses
Neuropathy
5
.03
Macular degeneration
2
.01
Kidney stones
2
.01
Sinusitis
2
.01
High cholesterol
17
.09
Incontinence
2
.01
Hypothyroid
8
.04
Gout
2
.01
Atrial fibrillation
2
.01
Blood clot
2
.01
Note. SCQ = Self-Administered Comorbidity Questionnaire. A total of 28 different write-in
responses were reported in the SCQ. Only write-in responses reported by 2 or more subjects are
included in this table.
4.4

Reliability Analyses
A series of reliability analyses were conducted on all scale items in order to determine

whether an acceptable level of internal consistency reliability was present among these items.
Table 4.7 presents the results of these analyses. Alphas above 0.70, indicating acceptable
reliability, were found in all cases with the exception of SCQ, which had a Cronbach’s alpha of
.36.
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Table 4.7
Reliability Analyses of Study Instruments
Instrument
DCS Total
DCS S1
DCS S2
DCS S3
DCS S4
DCS S5
SCQ

N Items
16
3
3
3
3
4

Alpha
.95
.91
.93
.75
.86
.88

16

.36

EORTC QLQ-C30
30
.88
Note. DCS = Decisional Conflict Scale, which consists of a global score and five subscales: S1
= informed; S2 = values clarity; S3 = support, S4 = uncertainty, and S5 = effective decision.
EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire, which consists of a global score, five function scales (physical, role,
emotional, cognitive, and social), three symptom scales (fatigue, pain, and nausea/vomiting), and
six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact).
SCQ = Self-Administered Comorbidity Questionnaire. All values were rounded to the nearest
hundredth decimal place.
4.5

Correlation analyses
A series of correlational techniques were conducted to determine the relationship

between treatment-related decisional conflict, QOL, and comorbidity in older adults with cancer.
Histograms and scatter plots indicated that these measures were not normally distributed. Given
the moderately positive skewness, the data were transformed using the square-root method
(Howell, 2007). Regeneration of histograms and scatterplots continued to demonstrate nonnormality of the data. Therefore, the assumptions of parametric testing were not met. Based on
this observation, Spearman's rho (rs) was conducted. First, the correlation conducted between
treatment-related decisional conflict and global health status/QOL was weak, though it was
positive and achieved statistical significance, rs (196) = .185, p = .009. This indicates that greater
treatment-related decisional conflict was weakly associated with greater QOL. Next, the
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correlation conducted between decisional conflict and comorbidity failed to achieve significance,
rs(196) = .129, p = .070. Finally, a weak to moderate but positive and significant correlation was
indicated between global health status/QOL and comorbidity, rs (198) = .240, p = .001. Although
the magnitude of this relationship was low, this result indicates that greater global health
status/QOL may be associated with greater comorbidity.
4.6

Regression analyses
Multiple linear regression analysis was then conducted in order to determine whether the

predictors of QOL and comorbidity significantly impact DCS total score as well as the individual
components of DCS. Table 4.8 summarizes the results of the multiple regression analysis
conducted on DCS total. Statistical significance was found with respect to emotional function,
diarrhea, and financial problems. Both emotional function as well as diarrhea had a negative
impact upon DCS total, while financial problems were found to have a positive impact.
Specifically, a one-unit increase in emotional function was associated with a .201 unit decrease
in DCS total (p=.001), while a one-unit increase in diarrhea was associated with a .131 unit
decrease in DCS total (p=.002). Additionally, a one-unit increase in financial problems was
associated with a .076 unit increase in DCS total (p=.024). This overall regression model was
found to achieve statistical significance with 15.9% of the variation in DCS total explained on
the basis of this regression model, F(16, 179) = 3.299, p < .001.
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Table 4.8
Regression Model Explaining Scores Reflecting DCS Total
Variable

B

Standard
Error
11.081
.053

Beta

t

p

(Constant)
38.654
3.488
.001
Global health
.079
.133
1.513
.132
status/QOL
Physical function
.072
.055
.141
1.314
.190
Role function
-.081
.064
-.186
-1.274
.204
Emotional function
-.201
.057
-.325
-3.519
**.001
Cognitive function
-.028
.061
-.043
-.454
.650
Social function
.040
.052
.083
.783
.435
Fatigue
-1.24
.079
-.217
-1.564
.120
Nausea/vomiting
-.068
.056
-.098
-1.209
.228
Pain
.075
.041
.153
1.844
.067
Dyspnea
.026
.037
.056
.696
.488
Insomnia
-.055
.034
-.121
-1.608
.110
Appetite loss
.019
.040
.041
.474
.636
Constipation
-.011
.031
-.026
-.344
.731
Diarrhea
-.131
.041
-.226
-3.173
**.002
Financial problems
.076
.033
.173
2.269
*.024
SCQ
-.045
.227
-.015
-.199
.842
2
Note. F(16, 179) = 3.299, p < .001; Adjusted R = .159. DCS = Decisional Conflict Scale. QOL
= quality of life. SCQ = Self-Administered Comorbidity Questionnaire. * = p < .05; ** = p <
.01.
Next, Table 4.9 presents the results of the regression analysis conducted on DCS 1
(informed subscale). Statistical significance was found with respect to emotional function,
cognitive function, financial problems, and the use of a spiritual support person in decision
making. Emotional function, cognitive function, and the use of a spiritual support person were all
found to have a negative impact upon DCS 1, while financial problems was found to have a
positive impact. Specifically, a one-unit increase in emotional function was associated with a
.191 unit decrease in DCS 1 (p=.007), while a one-unit increase in cognitive function was
associated with a .170 unit decrease in this outcome (p=.025). Next, a one-unit increase in
financial problems was associated with a .130 unit increase in DCS 1 (p=.002), while the use of a
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spiritual support person was associated with a 9.486 unit decrease in DCS 1 (p=.021). This
regression model also achieved statistical significance, with 19.7% of the variance in DCS 1
being explained on the basis of this regression model, F(18, 179) = 3.678, p < .001.

Table 4.9
Regression Model Explaining Scores Reflecting DCS Subscale 1 (Informed Subscale)
Variable

B

Standard
Error
13.589
.065

t

p

Beta
(Constant)
41.789
3.075
.002
Global health
.066
.088
1.029
.305
status/QOL
Physical function
.084
.069
.129
1.220
.224
Role function
-.077
.078
-.141
-.988
.324
Emotional function
-.191
.070
-.245
-2.722
**.007
Cognitive function
-.170
.075
-.207
-2.256
*.025
Social function
.118
.063
.191
1.854
.065
Fatigue
-.148
.097
-.206
-1.522
.130
Nausea/vomiting
-.062
.069
-.071
-.895
.372
Pain
.041
.050
.066
.814
.417
Dyspnea
.090
.046
.155
1.964
.051
Insomnia
-.075
.042
-.133
-1.788
.075
Appetite loss
-.050
.049
-.086
-1.026
.306
Constipation
.036
.039
.069
.923
.357
Diarrhea
-.090
.050
-.125
-1.796
.074
Financial problems
.130
.041
.235
3.165
**.002
SCQ
.185
.282
.049
.655
.513
Spiritual support
-9.486
4.065
-.162
-2.334
*.021
person
Other resources
-7.233
4.508
-.107
-1.605
.110
2
Note. F(18, 179) = 3.678, p < .001; Adjusted R = .197. DCS = Decisional Conflict Scale. QOL
= quality of life. SCQ = Self-Administered Comorbidity Questionnaire. * = p ≤ .05; ** = p <
.01.
Table 4.10 summarizes the results of the analysis conducted on DCS 2 (values clarity
subscale). In this analysis, statistical significance was found with respect to physical function,
emotional function, insomnia, and diarrhea. Physical function was found to have a positive
impact upon DCS 2, while all remaining significant predictors were found to have a negative
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impact. First, a one-unit increase in physical function was found to be associated with a .145 unit
increase in DCS 2 (p=.019), while a one-unit increase in emotional function was associated with
a .201 unit decrease in this outcome (p=.002). Next, a one-unit increase in insomnia was
associated with a .114 unit decrease in DCS 2 (p=.004), while a one-unit increase in diarrhea was
associated with a .107 unit decrease in DCS 2 (p=.020). This regression model achieved
statistical significance with 14.8% of the variance in DCS 2 explained on the basis of this
regression model, F(17, 179) = 3.006, p < .001.
Table 4.10
Regression Model Explaining Scores Reflecting DCS Subscale 2 (Values Clarity Subscale)
Variable

B

Standard
Error
12.303
.058

t

p

Beta
(Constant)
47.975
3.899
.000
Global health
.010
.016
.177
.859
status/QOL
Physical function
.145
.061
.255
2.370
*.019
Role function
-.132
.071
-.276
-1.866
.064
Emotional function
-.201
.063
-.293
-3.166
**.002
Cognitive function
-.073
.068
-.102
-1.072
.285
Social function
.008
.057
.014
.136
.892
Fatigue
-.169
.088
-.269
-1.923
.056
Nausea/vomiting
-.109
.062
-.142
-1.739
.084
Pain
.087
.045
.161
1.919
.057
Dyspnea
.077
.041
.151
1.860
.064
Insomnia
-.114
.039
-.230
-2.952
**.004
Appetite loss
.028
.044
.055
.630
.529
Constipation
-.012
.035
-.026
-.334
.738
Diarrhea
-.107
.046
-.167
-2.342
*.020
Financial problems
.065
.037
.135
1.764
.079
SCQ
-.412
.252
-.125
-1.631
.105
Cancer nurse helpful
3.278
2.055
.117
1.595
.112
Note. F(17, 179) = 3.006, p < .001; Adjusted R2 = .148. DCS = Decisional Conflict Scale. QOL
= quality of life. SCQ = Self-Administered Comorbidity Questionnaire. * = p < .05; ** = p <
.01.
Table 4.11 summarizes the results of the regression analysis conducted on DCS 3
(support subscale). In this analysis, statistical significance was indicated with respect to
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emotional function, fatigue, diarrhea, and year diagnosed. All of these predictors were found to
have a negative impact upon DCS 3. First, a one-unit increase in emotional function was
associated with a .140 unit decrease in DCS 3 (p=.012), while a one-unit increase in fatigue was
associated with a .167 unit decrease in DCS 3 (p=.031). Next, a one-unit increase in diarrhea was
associated with a .133 unit decrease in DCS 3 (p=.001), while a one-unit increase in year
diagnosed was associated with a .744 unit decrease in DCS 3 (p=.002). This regression model
was found to achieve statistical significance, with 15.7% of the variation DCS 3 explained on the
basis of this model, F(17, 176) = 3.107, p < .001.
Table 4.11
Regression Model Explaining Scores Reflecting DCS Subscale 3 (Support Subscale)
Variable
B
Standard
t
p
Error
Beta
(Constant)
1529.501
472.413
3.238
.001
Global health
.089
.051
.154
1.730
.085
status/QOL
Physical function
.059
.054
.121
1.101
.273
Role function
-.114
.061
-.272
-1.851
.066
Emotional function
-.140
.055
-.236
-2.538
*.012
Cognitive function
.021
.059
.033
.350
.727
Social function
.023
.050
.049
.455
.650
Fatigue
-.167
.077
-.304
-2.177
*.031
Nausea/vomiting
-.025
.055
-.038
-.456
.649
Pain
.052
.039
.111
1.323
.187
Dyspnea
.033
.036
.074
.902
.368
Insomnia
-.004
.033
-.010
-.136
.892
Appetite loss
.041
.039
.093
1.059
.291
Constipation
-.038
.030
-.095
-1.261
.209
Diarrhea
-.133
.039
-.244
-3.392
**.001
Financial problems
.057
.032
.137
1.782
.076
SCQ
-.138
.221
-.048
-.625
.533
Year diagnosed
-.744
.235
-.223
-3.171
**.002
2
Note. F(17, 176) = 3.107, p < .001; Adjusted R = .157. DCS = Decisional Conflict Scale. QOL
= quality of life. SCQ = Self-Administered Comorbidity Questionnaire. * = p < .05; ** = p <
.01.
Table 4.12 presents the results of the regression analysis conducted on DCS 4
(uncertainty subscale). In this analysis, statistical significance was found with respect to
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emotional function, diarrhea, and financial problems. Both emotional function as well as diarrhea
was found to have a negative impact upon DCS 4, while financial problems was found to have a
positive impact. Specifically, a one-unit increase in emotional function was associated with a
.233 unit decrease in DCS 4 (p=.006), while a one-unit increase in diarrhea was associated with a
.146 unit decrease in DCS 4 (p=.018). Additionally, a one-unit increase in financial problems
was associated with a .105 unit increase in DCS 4 (p=.034). This regression model also achieved
significance with 14.4% of the variation in DCS 4 explained on the basis of this model, F(17,
180) = 2.957, p < .001.
Table 4.12
Regression Model Explaining Scores Reflecting DCS Subscale 4 (Uncertainty Subscale)
Variable

B

Standard
Error
16.382
.077

t

p

Beta
(Constant)
48.454
2.958
.004
Global health
.123
.140
1.591
.113
status/QOL
Physical function
.014
.081
.019
.175
.862
Role function
-.042
.094
-.066
-.448
.655
Emotional function
-.233
.084
-.257
-2.766
**.006
Cognitive function
-.090
.090
-.094
-.992
.323
Social function
.021
.076
.029
.271
.786
Fatigue
-.172
.117
-.206
-1.461
.146
Nausea/vomiting
-.080
.083
-.079
-.958
.339
Pain
.115
.060
.160
1.918
.057
Dyspnea
-.010
.056
-.015
-.175
.861
Insomnia
-.061
.050
-.092
-1.207
.229
Appetite loss
.029
.059
.043
.502
.617
Constipation
.001
.046
.001
.014
.989
Diarrhea
-.146
.061
-.174
-2.395
*.018
Financial problems
.105
.049
.164
2.140
*.034
SCQ
.001
.337
.000
.002
.998
Chemotherapy
7.224
3.892
.135
1.856
.065
2
Note. F(17, 180) = 2.957, p < .001; Adjusted R = .144. DCS = Decisional Conflict Scale. QOL
= quality of life. SCQ = Self-Administered Comorbidity Questionnaire. * = p < .05; ** = p <
.01.
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Table 4.13 summarizes the results of the regression analysis conducted on DCS 5
(effective decision subscale). Statistical significance was found with respect to global health
status/QOL, emotional function, nausea/vomiting, diarrhea, and the use of a spiritual support
person in decision making. Each of these predictors was found to have a negative impact upon
DCS 5 with the exception of global health status/QOL. First, a one-unit increase in QOL was
found to be associated with a .117 unit increase in DCS 5 (p=.043), while a one-unit increase in
emotional function was associated with a .239 unit decrease in DCS 5 (p=.000). Next, a one-unit
increase in nausea/vomiting was associated with a .132 unit decrease in DCS 5 (p=.032), while a
one-unit increase in diarrhea was associated with a .133 unit decrease in DCS 5 (p=.003).
Finally, the use of a spiritual support person was associated with a 10.956 unit decrease in DCS 5
(p=.002). This regression model was found to achieve statistical significance, with 15.4% of the
variation in DCS 5 explained on the basis of this analysis, F(17, 179) = 3.096, p < .001 .
Table 4.13
Regression Model Explaining Scores Reflecting DCS Subscale 5 (Effective Decision Subscale)
Variable
(Constant)
Global health
status/QOL
Physical function
Role function
Emotional function
Cognitive function
Social function
Fatigue
Nausea/vomiting
Pain
Dyspnea
Insomnia
Appetite loss
Constipation
Diarrhea

B
28.155
.117

Standard
Error
12.055
.057

.050
-.024
-.239
.121
-.022
-.101
-.132
.073
-.009
-.030
.061
-.006
-.133

.060
.069
.062
.067
.056
.086
.061
.044
.041
.037
.043
.035
.045
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t

p

Beta
.180

2.336
2.039

.021
*.043

.090
-.051
-.356
.171
-.042
-.163
-.176
.137
-.019
-.060
.121
-.014
-.214

.838
-.344
-3.847
1.818
-.398
-1.169
-2.159
1.648
-.233
-.792
1.405
-.177
-2.979

.403
.731
**.000
.071
.691
.244
*.032
.101
.816
.429
.162
.859
**.003

Financial problems
.036
.036
.076
.999
.319
SCQ
.156
.250
.048
.623
.534
Spiritual support
-10.956
3.563
-.217
-3.075
**.002
person
Note. F(17, 179) = 3.096, p < .001; Adjusted R2 = .154. DCS = Decisional Conflict Scale. QOL
= quality of life. SCQ = Self-Administered Comorbidity Questionnaire. * = p < .05; ** = p <
.01.
4.7

Results and Discussion
This study was conducted in an attempt to answer two research questions. The results of

the descriptive data and the data analyses in regard to the relationships between and among the
variables of decisional conflict, QOL, and comorbidity will be discussed in this section.
Discussion will also include findings relative to the modified Ottawa Decision Support
Framework (ODSF), which provided the theoretical framework for this study.
Complex decisions related to chemotherapy and radiation therapy accounted for the
majority of the sample (n=169, 84.9%). This statistic is not surprising given that treatmentrelated side effects of chemotherapy and radiation therapy can vary greatly and can negatively
affect the natural history of cancer (Balducci, 2009; Extermann, 2007; Muss, 2009; Zeber et al.,
2008). In this sample, 87% of subjects reported that they had received chemotherapy for their
cancer. Older adults with cancer make their treatment decisions depending on the burden of the
treatment, possible outcomes, and likelihood of adverse functional and cognitive outcomes
(Fried, Bradley, Towle, & and Allore, 2002).
In regard to the demographic characteristics of this sample, there were some similarities
and differences when compared to national data. A slight majority of this sample was female
(n=102, 51%) compared to national data indicating that the majority of new cancer cases are men
(n=854,790, 51%) (American Cancer Society [ACS], 2013). Of note, the national data takes into
account all ages of cancer cases, not just older adults. The mean age of subjects in this sample
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was 73.1 years, which is consistent with national data that shows cancer rates highest in people
aged 65-74 years (National Cancer Institute [NCI], 2013). Unlike national data, the majority of
this sample (88.8%) was white (Siegel, Ma, Zou, & Jemal, 2014).
Similar to another study (Krok, Baker, & McMillan, 2013), the diagnoses of lung cancer,
leukemia, MDS, and lymphoma comprised the majority of this study sample. In this sample,
lung cancer was the most reported cancer type (n=46, 23.1%). In national data, lung cancer is
the third most common type of cancer (13.7%) diagnosed for all ages (NCI, 2013). In New
Jersey, where this study was conducted, lung cancer is the second most common type of cancer
(12%) diagnosed for all ages (ACS, 2013). With regard to older adults, patients 70 years and
older account for 47% of all lung cancers (Owonikoko et al., 2007).
Slightly less than half of this sample reported that their cancer had spread from its
primary site. The probability of developing invasive cancer increases with age (ACS, 2013).
According to data from the ACS (2013), the probability of developing invasive cancer increases
from 8.79% in men between ages 40 to 59; from 16.03% between the ages of 60 to 69; and, from
38.07% at age 70 and older.
Subjects in this sample were diagnosed with cancer between 1998 and 2013 (M=2011,
SD=3.52). The 5-year relative survival for all ages and all cancer types is 65.8% (NCI, 2013).
According to the NCI (2013), older adults account for a higher percentage of survivors (59%)
when compared to younger individuals.
Family members were a source of support for the participants in this study. Over
seventy-five percent of the sample indicated that they were accompanied to appointments with
their cancer doctors by a spouse/significant other, child, or other family member. Only 19% of
the sample went to cancer-related appointments alone. According to Kreling, Figueiredo,
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Sheppard, and Mandelblatt (2006), the availability of a caregiver or a family member influences
treatment decisions and, to some extent, could lead to disagreement among family members
(Schafer et al., 2006; Zhang & Siminoff, 2003). Family was also integral in making decisions
about cancer treatment. In this sample, participants reported multiple sources of support in
making decisions about cancer treatment including the cancer doctor (99%), family (80%), and
cancer nurse (37%). This is consistent with other studies that demonstrated the importance of
family preference, family burden, and physician’s opinion in making cancer-related treatment
decisions (Kohara & Inoue, 2010; Kutner et al., 2000; Kutner, Vu, Prindiville, & Byers, 2000).
According to O’Connor (2010), a DCS score less than 25 indicates no decision-making
difficulty. The mean DCS total score of 22.064 (SD=12.480) demonstrated that, overall, the
participants in this study did not have difficulty with decision making. This result should be
interpreted cautiously, however, given the finding by Chien, Chuang, Liu, Li, and Liu (in press)
that DCS scores reduced considerably up to six months post-treatment. Since almost 63% of the
sample made the treatment-related decision within the last six months, the actual level of
decisional conflict may have been higher at the time of the decision. Participants did
demonstrate a higher level of decisional conflict (M=29.167) in DCS subscale four which
evaluates how informed one is “about options, risks, and benefits, and feeling clear about values
and value tradeoffs in the decision” (O'Connor, 1995, p. 26). A higher score in this subscale
indicates that participants felt less informed about options, risks, and benefits and were unsure of
personal values in making cancer treatment-related decisions.
When compared with data from other studies of older adults with cancer, the global
health status/QOL of this sample was generally poorer. In this study, the mean score on the two
global health status/QOL questions was 44.2 (Range=0.0 - 100.0, with a higher score
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representing a higher QOL). In a large study of cancer patients by Scott et al. (2008) to establish
reference values for the EORTC QLQ-C30, the mean global health status/QOL was found to be
61.8 (ages 60-69) and 60.6 (ages 70 and older). Although different instruments were used to
measure QOL, the overall QOL of this sample is poorer than the QOL of older adults with cancer
or advanced illness in other studies (Black et al., 2011; Solomon, Kirwin, Van Ness, O'Leary, &
Fried, 2010).
The EORTC QLQ-C30 incorporates five functional scales, including physical, role,
cognitive, emotional, and social. According to the developers of the instrument, “a high score
for a functional scale represents a high/healthy level of functioning” (Fayers et al., 2001, p. 6).
When compared with the EORTC QLQ-C30 reference values (Scott et al., 2008) for patients 70
years and older, the participants in this study had poorer physical function (M=72.1 vs 64.1,
respectively), poorer role function (M=70.7 vs. 59.8, respectively), better emotional function
(M=76.1 vs. 79.0, respectively), similar cognitive function (M=81.0 vs. 80.1, respectively), and
poorer social function (M=78.2 vs. 68.3).
The remainder of the EORTC QLQ-C30 consists of three symptom scales (fatigue, pain,
nausea, and vomiting) and six single items addressing symptoms (dyspnea, insomnia, appetite
loss, constipation, diarrhea, and financial problems). A higher score for these items represents a
higher level of symptomatology/problems (Fayers et al., 2001). With the exception of insomnia,
the participants in this study had higher mean scores on all symptom scales and single items than
the EORTC QLQ-C30 reference values. The mean insomnia scores were similar. The fact that
participants in this study, overall, had poorer role function and worse symptomatology may
account for their report of poorer global health status/QOL.
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The reported level of comorbidity by participants in this study was higher than in other
studies of older adults that utilized the SCQ (Merriman et al., in press; Schjolberg, Dodd,
Henriksen, & Rustoen, 2011). Interestingly, though, the number of medications reported was
lower than expected in older adults (M=6.38 vs. 14, respectively) (American Society of
Consultant Pharmacists, 2013). Other than cancer, the most reported comorbid illnesses were
high blood pressure (71.2%), back pain (36%), lung disease (33.5%), diabetes (28%),
osteoarthritis (26.5%), heart disease (23%), anemia (22.5%), and depression (19%). These
illnesses were similar to the most reported illness in other studies of older adults (Sangha et al.,
2003; Sarna et al., 2005; Schjolberg et al., 2011).
4.7.1 Research question 1: What is the relationship between and among treatmentrelated decisional conflict, QOL, and comorbidity in older adults with cancer?
A series of correlational techniques was conducted to determine the relationship between
treatment-related decisional conflict, QOL, and comorbidity. Correlational analysis indicated
that decisional conflict as measured by DCS total score was significantly correlated with QOL
(as measured by global health status/QOL) (rs (196) = .185, p = .009). The weak, though
positive, correlation indicates that greater treatment-related decisional conflict was associated
with greater QOL. This finding may suggest that patients feel conflicted about how cancer
treatments will impact a higher QOL. Fried, Bradley, Towle, and Allore (2002) found that older
adults with cancer chose their treatment decisions depending on the burden of the treatment,
possible outcomes, and likelihood of adverse functional and cognitive outcomes. To date, there
have been no published studies that document the relationship between decisional conflict and
QOL.
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Correlational analysis indicated that QOL as measured by global health status/QOL was
significantly correlated with comorbidity as measured by SCQ (rs (198) = .240, p = .001). The
weak to moderate, though positive, correlation indicates that greater QOL may be associated
with greater comorbidity. This is contradictory to a study of lung cancer patients that
demonstrated severe comorbidity to be associated with poor QOL (Gronberg et al., 2010). It is
important to note, however, that the instruments used to measure QOL and comorbidity were
different than those used in this study.
Finally, correlational analysis indicated that decisional conflict as measured by DCS total
scores and comorbidity as measured by the SCQ were not significantly correlated (rs (196) =
.129, p = .070). In this study, the SCQ was not found to have an acceptable level of internal
consistency (α=.358). Since Cronbach’s alpha is an indicator of an instrument’s quality, this
finding is concerning. When an instrument is unreliable, the risk of a Type II error increases. In
this study, this could mean that there may have been a significant relationship between decisional
conflict and comorbidity.
4.7.2 Research question 2: To what degree does the variability in QOL and level of
comorbidity predict decisional conflict in decision making?
Multiple linear regression analysis was conducted in order to determine whether the
predictors of QOL and comorbidity significantly impact the DCS total score and the five DCS
subscales. All six of the regression models were found to achieve statistical significance (p
<.001).
Statistical significance was found with respect to emotional function in all six regression
models. As emotional function scores increased, scores decreased in DCS total, informed
subscale, values clarity subscale, support subscale, uncertainty subscale, and effective decision
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subscale. Simply, these findings indicate that higher/healthier emotional function may be
predictive of lower decisional conflict. Additionally, with regard to the subscales,
higher/healthier emotional function may be predictive of feeling informed about options, risks,
and benefits; being clear about personal values; feeling supported in decision making; feeling
certain about decision; and feeling that an effective decision has been made.
Previous studies have documented a relationship between decisional conflict and
emotional status, with mixed results. In a study of hospital patients (Knops et al., 2013), a
decrease in decisional conflict lead to less fretting (p=.00) and nervousness (p=.01). Rini et al.
(2009) found a similar relationship to the present study with a negative predictive relationship
between anxiety and DCS (p=.02).
Financial problems reported as a component of the EORTC QLQ-C30 were statistically
significant in the regression models for DCS total scores, the informed subscale, and the
uncertainty subscale. There was a positive relationship documented, with financial problem
scores increasing as DCS total, informed subscale, and uncertainty subscale scores increased.
This indicates that financial problems were found to be predictive of higher decisional conflict
overall, as well as in the two subscales. Lack of insurance and having a poor financial status are
important contextual factors that can influence treatment choice (Bailey et al., 2003;
Mandelblatt, Yabroff, & Kerner, 1999; Schrag, Cramer, Bach, & Begg, 2001).
Interestingly, of those physical symptoms that achieved significance, a negative
relationship was found. The symptom of diarrhea reported as a component of the EORTC QLQC30 was significant in five of the six models with the exception of the informed subscale. Other
symptoms that were found to be significant included insomnia (values clarity subscale), fatigue
(support subscale), and nausea/vomiting (effective decision subscale). This is a curious finding,
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as it would seem that worse physical symptoms, especially if they were treatment-related, may
increase decisional conflict. Although an explanation for this finding is unclear, it may be that
participants felt that the symptoms are expected with the cancer treatment and, thus, did not
increase conflict in the decision making process. Alternatively, if the symptoms are cancerrelated, participants may have felt that the treatment was helping them.
In prior studies, the presence of spiritual support has been documented to impact
treatment-related decisions (Balboni et al., 2010; True et al., 2005). In this study, the use of a
spiritual support person for decision making (reported as a component of the demographic
information form) significantly decreased scores in the informed and effective decision
subscales. There are no published studies to date examining the relationship between spiritual
support and decisional conflict and, thus, additional research is needed to confirm this finding.
4.8

Application of the modified Ottawa Decision Support Framework (ODSF)
The investigator-modified ODSF was the guiding framework for this study. The ODSF

was developed to address decisional conflict and includes three variables: decisional needs,
decisional quality, and decision support. The variable of decisional needs includes factors such
as: decision [type, timing, stage, and leaning, which is defined as “the inclination to choose one
option over the other” (O'Connor, 2006, p. 3)]; decisional conflict; knowledge and expectations;
values; support and resources (others’ opinions/practices, pressure, role in decision making,
experience, self-efficacy, motivation, skill, and external support); and personal and clinical
characteristics (O'Connor, 2006). The ODSF was modified to include the variables of comorbid
illness and QOL (Figure 4.1). This model was useful for framing this study, as two of the three
relationships were significant. There was a weak, positive association between decisional
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conflict and QOL and a weak to moderate, positive association between QOL and comorbid
illness. The association between decisional conflict and comorbidity failed to reach significance.

Quality
Of Life

Comorbid
Illness








Decisional Needs:
Decision
Decisional conflict
Knowledge & expectations
Values
Support & resources
Personal & clinical
characteristics







Decision Quality:
Quality of the decision
Quality of the decision
making process

Decision Support:
Patient decision aids
Decision coaching

Figure 2. Modified Ottawa Decision Support Framework (ODSF).
The ODSF was modified to include the variables of comorbid illness and quality of life. These
variables have been linked to the existing ODSF as indicated by the dotted lines. From “Ottawa
Decision Support Framework to address decisional conflict,” by O’Connor, 2006, retrieved from
http://www.ohri.ca/decisionaid. Adapted with permission.
4.9

Conclusion
This chapter served to report the data analysis for this study. Initially, the results of the

pilot study were reported followed by an explanation of the changes made to the investigatordeveloped instructions for the DCS. Next, the relationships between and among decisional
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conflict, QOL, and comorbidity were explored. Overall, the level of decisional conflict in this
study sample was found to be low. Study findings suggest that there may be positive
relationships between decisional conflict and QOL, as well as QOL and comorbidity.
Additionally, multiple linear regression analyses conducted found significant results, with a
moderately high percentage of variance explained in all six regression models. All six regression
models were found to achieve statistical significance.
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CHAPTER 5
RESULTS /MANUSCRIPT
This study examined the relationships between and among cancer treatment-related
decisional conflict, comorbidity, and quality of life in older adults with cancer. This chapter is
presented as a results manuscript that will be submitted for publication. The chapter has been
formatted for journal submission and the following major categories are addressed: abstract,
literature review, research questions, methods, analyses, results, discussion, limitations,
implications for nursing, and directions for future research.
5.1

Structured Abstract

Purpose: To examine the relationships between and among cancer treatment-related decisional
conflict, quality of life, and comorbidity in older adults with cancer.
Design: A cross-sectional, descriptive, correlational design.
Setting: Outpatient medical oncology, radiation oncology, and palliative care practices in the
northeastern United States.
Sample: 200 patients aged 65 years and older currently receiving treatment for cancer
Methods: An anonymous survey method was employed. Survey instruments included:
Decisional Conflict Scale; Self-Administered Comorbidity Questionnaire; European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire; and, an
investigator-developed Demographic Information Form.
Main Research Variables: Decisional conflict, quality of life, and comorbidity
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Findings: Bivariate relationships existed between increased levels of decisional conflict and
increased quality of life (p = .009) and quality of life and comorbidity (p = .001). All six
regression models achieved significance (p < .001). Three to five statistically significant
relationships were identified in each of the six regression models.
Conclusions: Results may suggest a relationship between decisional conflict and quality of life,
as well as quality of life and comorbidity. There are several factors that may positively or
negatively influence decisional conflict.
Implications for Nursing: With their focus on patient-centered care, oncology nurses are a
crucial component of the multidisciplinary cancer team that can empower older cancer patients
to communicate their values and preferences regarding cancer treatment.
Knowledge Translation: Cancer care in older adults is complex. It is important to understand
that physical, cognitive, financial, spiritual and psychosocial factors can affect how older adults
approach cancer treatment-related decisions and how much decisional conflict they have.
5.2

Introduction/Literature Review
It is widely accepted that the single greatest risk factor for cancer is age. Sixty percent of

cancers and two-thirds of cancer deaths occur over the age of 65 years (National Cancer Institute,
2009). As the population ages, this proportion will markedly increase.
The incidence of comorbid illness also increases with age. On average, people 65 years of
age and over, with cancer, suffer from three additional diseases (Extermann, 2000; Marenco et
al., 2008). Comorbidity is associated with reduced life expectancy and increased risk for
treatment complications, while also having the potential to negatively affect the natural history of
cancer (Balducci, 2009; Extermann, 2007; Muss, 2009; Zeber et al., 2008).
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Regardless of age, cancer treatment-related decisions can be exceedingly complex. There
is variability in patients’ desire to participate in decision making, which may be influenced by
their age and disease progression (Barry & Henderson, 1996; Degner & Sloan, 1992; Petrisek,
Laliberte, Allen, & Mor, 1997; Yogaparan et al., 2009). Additionally, there are a variety of
psychological, physical, functional, and social factors that influence decision making (Chen,
Haley, Robinson, & Schonwetter, 2003; Gauthier & Swigart, 2003; Kelly-Powell, 1997; Kohara
& Inoue, 2010). With an increasing number of cancer treatments available, patients are presented
with increasingly difficult decisions. These decisions can lead to decisional conflict, which can
be described as “a state of uncertainty about which course of action to take when choices among
competing actions involve risk, loss, regret, or challenge to personal life values” (Legare,
O'Connor, Graham, Wells, & Tremblay, 2006, p. 374). Physiologic and psychological factors
can be the basis for patients’ decision making. For older adults, decisions regarding treatment
may be considered in the context of physical function. Sometimes, patients will choose to forego
cancer treatment explicitly within the context of their age and comorbidities (Sinding,
Wiernikowski, & Aronson, 2005). Decision making is preceded by careful thought, which is
influenced by a broad perspective of older adults’ values and their perceptions of their whole life
situation (Hughes, Closs, & Clark, 2009; Thome, Dykes, Gunnars, & Hallberg, 2003).
Quality of life (QOL) is a concept that is central to the care of all patients. QOL is
generally described as being subjective and multidimensional (Cella, 1992). Subjectivity refers
to the fact that QOL can be understood only from the patient’s perspective; QOL can only be
assessed appropriately by asking the patient about it directly. Patients' responses are influenced
by their current set of expectations surrounding their actual functional level, as well as their
perceptions about the treatment environment (Cella, 1992). The multidimensional component of
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QOL refers to the coverage of a broad range of content, including physical functioning or wellbeing, psychological well-being, social role functioning or well-being, disease- and treatmentrelated symptoms, and spiritual well-being (Cella, 1992; Dunn et al., 2003; Ferrans, 1990).
As the proportion of older adults in the world increases, so too will the prevalence of
cancer. Cancer will be just one of the chronic illnesses that older adults will endure. Older adults
are at risk for physical, psychological, and functional decline as a result of these chronic
illnesses, which may be exacerbated by cancer and cancer treatment. Cancer treatment-related
decisions are multifactorial and complex for health care providers, patients, and families.
Although physicians utilize clinical tools in making decisions regarding treatment, little is known
about how older adults make their own decisions regarding treatment and whether they
experience decisional conflict regarding those decisions.
The investigator-modified ODSF was the guiding framework for this study. The ODSF
was developed to address decisional conflict and includes three variables: decisional needs,
decisional quality, and decision support. The variable of decisional needs includes factors such
as: decision [type, timing, stage, and leaning, which is defined as “the inclination to choose one
option over the other” (O'Connor, 2006, p. 3)]; decisional conflict; knowledge and expectations;
values; support and resources (others’ opinions/practices, pressure, role in decision making,
experience, self-efficacy, motivation, skill, and external support); and personal and clinical
characteristics (O'Connor, 2006). This framework was appropriate for this study as it is
intended for all participants involved in decision making and was proposed, specifically, to
address decisional conflict. The ODSF was modified to include the variables of comorbid illness
and QOL.
5.3

Research Questions
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The purpose of this study was to examine the relationships between and among treatmentrelated decisional conflict, comorbid illness, and QOL in older adults with cancer. The
following research questions guided this inquiry:

1.

What is the relationship between and among treatment-related decisional conflict,

QOL, and comorbidity in older adults with cancer?
2.

To what degree does the variability in QOL and level of comorbidity predict

decisional conflict?

5.4

Methods
5.4.1

Design/setting

The study utilized a cross-sectional, descriptive, correlational study design using a survey
method. After obtaining approval from the Institutional Review Board (IRB) at Duquesne
University, recruitment began in two medical oncology practices, a radiation oncology practice,
and a palliative care practice in the northeastern United States. A nursing representative in each
office was identified as a key person for assistance in identification of potential subjects and
communication regarding the study. If patients met inclusion criteria, they were offered a survey
packet to complete. Participants were compensated with a $10 gift card for participation in this
study. All participants were anonymous to the investigator.
5.4.2

Participants

Criteria for inclusion in this study were: (a) 65 years of age or older, (b) Englishspeaking, (c) ability to read English at an eighth grade level, (d) having a current cancer
diagnosis, and (e) receiving cancer treatment. A power analysis was conducted to determine the
appropriate sample size to conduct correlational statistics and regression analysis. Thus, a
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sample size of 193 was needed to achieve power of .80 using a two tailed test of significance at
.05. A sample size of 200 was recruited for this study.
5.4.3

Instruments

Participants were asked to complete four instruments including: Decisional Conflict Scale
(DCS) (O'Connor, 1995), Self-Administered Comorbidity Questionnaire (SCQ) (Sangha, Stucki,
Liang, Fossel, & Katz, 2003), European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC QLQ-C30) (Aaronson et al., 1993), and an investigatordeveloped Demographic Information Form (DIF).
The DCS (O'Connor, 1995) was developed to elicit “healthcare consumers’ uncertainty in
making a health-related decision, the factors contributing to the uncertainty, and health-care
consumers’ perceived effective decision making” (p. 25). Because cancer patients are faced with
many decisions, the investigators decided to focus participants on their opinions regarding a
treatment decision specific to the area of inquiry.

To this end, we developed a paragraph that

focuses respondents to cancer treatment-related decisions, an open-ended question to determine
the decision that was made, and a multiple choice question to determine when the decision was
made. The paragraph and questions were pilot-tested with a sample (n = 10) that met the
inclusion criteria for the current study. Minor logistical revisions were made based on the pilot
study.
The traditional DCS is a 16-item instrument that consists of five subscales: informed
(items 1-3); values clarity (items 4-6); support (items 7-9); uncertainty (items 10-12); and
effective decision (items 13-16). Items in each subscale are scored on a 5-point Likert scale (0 =
strongly agree, 1 = agree, 2 = neither agree nor disagree, 3 = disagree, and 4 = strongly disagree).
The DCS takes approximately five to ten minutes to complete. The DCS has met acceptable
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standards of reliability and validity. It was initially tested in two decision-making contexts:
breast cancer screening and influenza immunization (n = 909) (O'Connor, 1995). The test-retest
correlation coefficient was 0.81. The DCS consistently discriminated significantly (p < 0.0002)
between those who accepted/rejected and those who delayed/were unsure of the invitation to be
immunized/screened (O'Connor, 1995). In this study, reliability analyses indicated acceptable
reliability with Cronbach’s alphas above .70 (Polit, 2010) for the DCS total score and each of the
subscales.
The SCQ allows participants to note the severity of each comorbid disease and their
perception of its impact on their function (Sangha et al., 2003). It is a 13-item instrument with
the option of adding three additional conditions in an open-ended format. The SCQ can be
completed in approximately five to ten minutes. The test-retest reliability for the SCQ was
studied in a sample of 170 patients over 50 years of age. The test-retest reliability for the SCQ in
26 patients was 0.94 (95% CI 0.72, 0.99) as calculated by the intraclass correlation coefficient
and 0.81 by the Spearman correlation coefficient (Sangha et al., 2003). In this study, the SCQ
was not found to have an acceptable level of reliability (Cronbach’s α = .36) (Polit, 2010).
The EORTC QLQ-C30 (Version 3) is a 30-item instrument that consists of multi-item
scales and single-item measures including five function scales, three symptom scales, a global
health status/QOL scale, and six single items. The two global health status/QOL items are
scored on a 7-point Likert scale (1 = very poor and 7 = excellent); the remaining 28 items are
scored on a 4-point Likert scale (1 = not at all, 2 = a little, 3 = quite a bit, and 4 = very much).
All of the scales and single-item measures range in score from 0 to 100. A high scale score
represents a higher response level. The EORTC QLQ-C30 takes approximately ten minutes to
complete. Psychometric properties of the EORTC QLQ-C30 were evaluated in an international
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field study that was conducted in 13 countries with 305 patients with nonresectable lung cancer
(Aaronson et al., 1993). The role functioning scale was the only multi-item scale that failed to
meet the minimal standards for reliability (Cronbach’s α ≥ 0.70) either before or after treatment.
In general, the interscale correlations were moderate indicating that, although related, they are
assessing distinct components of the QOL construct (Aaronson et al., 1993). In this study, the
EORTC QLQ-C30 was found to have an acceptable level of reliability (Polit, 2010) with a
Cronbach’s alpha of .88.
The DIF included 17 items to describe the population under study. In addition to marital
status, race, religion, and education, participants were asked to indicate how many prescription
and over-the-counter medications they were taking. Furthermore, there were questions to specify
the type of cancer, types of cancer treatments received, and types of decision support.
5.5

Analysis
Data were analyzed using IBM SPSS Statistics Version 21.0 (2012). Initially, histograms

as well as additional descriptive analyses conducted indicated that these data were not normally
distributed; therefore, the assumptions of parametric testing were not met. A series of
descriptive statistics were conducted on the demographic data and on the dependent variable,
decisional conflict, and independent variables, QOL and comorbidity. Next, a series of
correlations were conducted in order to determine the relationship between the variables. Since
the assumptions for parametric testing were not met, Spearman’s rho (rs), the nonparametric
equivalent of Pearson’s product-moment correlation (r), was used for the correlational analyses.
In addition, multiple linear regression analyses were conducted to determine whether the
predictors of QOL and comorbidity significantly impact decisional conflict.
5.6

Results
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The sample was 51% female (n = 102) with a mean age of 73.10 years (SD = 6.98; Range
= 65-92) (see Table 1). The majority where white (87.5%; n = 175) and retired (71.5%; n =
143). The most common cancer diagnosis was lung cancer (23.1%; n = 46). Slightly over 41%
of participants indicated they are accompanied by spouses/significant others to appointments
with their cancer doctors. Approximately 19% of participants reported that they go alone to
cancer appointments. In terms of decision support, almost all (99%, n = 198) reported that their
cancer doctor helped them make decisions about their cancer treatment. Eighty- percent of
participants (n = 160) identified their family as helpful in decision making and 37% (n = 74)
reported that their cancer nurse was helpful in decision making.
The majority of participants (59%; n = 118) identified their complex decision as related to
chemotherapy and 48% of the participants indicated that they had made their decision within the
last three months. Approximately 19% of participants had made the decision over one year ago.
See Table 2 for a summary of the demographic characteristics of the sample.
A summary of the descriptive statistics for the DCS, EORTC QLQ-C30, and SCQ is
presented in Table 3. The mean DCS total score was 22.1 (SD = 12.5; Range = 0.0 - 70.3; scale
Range = 0.0 - 100.0). Subscale four (uncertainty) was found to be the highest of the subscales,
with a mean of 29.2 (SD = 18.2; Range = 0.0 - 100.0; scale Range = 0.0 - 125.0). The mean
score on the two global health status/QOL questions was 44.2 (SD = 20.7; Range = 0.0 - 100.0;
scale Range = 0.0 - 100.0). Of the function scales, cognitive function had the highest mean score
(M = 80.1; SD = 18.8; Range = 16.7 - 100.0; scale Range = 0.0 - 100.0), while role function had
the lowest (M = 59.8; SD = 28.6; Range = 0.0 - 100.0; scale Range = 0.0 - 100.0). Fatigue had
the highest mean of the symptom scales (M = 41.4; SD = 21.6; Range = 0.0 - 100.0; scale Range
= 0.0 - 100.0). With regard to the six single items, dyspnea had the highest mean of 28.3 (SD =
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26.7; Range = 0.0 - 100.0; scale Range = 0.0 - 100.0). The mean score of the SCQ was 9.6 (SD
= 4.1; Range = 3.0 - 23.0; scale Range = 0.0 - 48.0). Other than cancer (n = 198, 99%), the most
reported comorbid illness was high blood pressure (n = 142, 71%).
See Table 3 for correlation coefficients for each of the study variables. The correlation
analysis conducted between treatment-related decisional conflict and global health status/QOL
was weak, though it was positive and achieved statistical significance (rs (196) = .185, p = .009).
Next, a weak to moderate but positive and significant correlation was indicated between global
health status/QOL and co-morbidity, (rs (198) = .240, p = .001). Finally, no relationship was
found between decisional conflict and co-morbidity.
Multiple linear regression analysis was conducted in order to determine whether the
predictors of QOL and comorbidity significantly impact decisional conflict, as measured by the
DCS total score and the five DCS subscales (informed, values clarity, support, uncertainty, and
effective decision). All six of the regression models were found to achieve statistical
significance (p < .001). Table 4 provides a summary of the significant relationships. Emotional
function (β = -.325, p = .001) and diarrhea (β = -.226, p = .002) had a negative impact upon DCS
total, while financial problems (β = .173, p = .024) were found to have a positive impact. For
DCS 1 (informed subscale), emotional function (β = -.245, p = .007), cognitive function (β = .207, p = .025), and the use of a spiritual support person (β = -.162, p = .021) were found to have
a negative impact, while financial problems (β = .235, p = .002) was found to have a positive
impact. Physical function (β = .255, p = .019) was found to have a positive impact upon DCS 2
(values clarity subscale), while emotional function (β = -.293, p = .002), insomnia (β = -.230, p =
.004), and diarrhea (β = -.167, p = .020) had a negative impact. Emotional function (β = -.236, p
= .012), fatigue (β = -.304, p = .031), diarrhea (β = -.244, p = .001), and year of diagnosis (β = -
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.223, p = .002) were found to have a negative impact on DCS 3, (support subscale). For DCS 4
(uncertainty subscale), emotional function (β = -.257, p = .006) and diarrhea (β = -.174, p = .018)
had a negative impact; financial problems (β = .164, p = .034) was found to have a positive
impact. Finally, with regard to DCS 5 (effective decision subscale), global health status/QOL (β
= .180, p = .043) was found to have a positive impact, while emotional function (β = -.356, p =
.000), nausea/vomiting (β = -.176, p = .032), diarrhea (β = -.214, p = .003), and the use of a
spiritual support person (β = -.217, p = .002) had a negative impact.
5.7

Discussion
Similarities as well as differences were found in the demographic characteristic of this

sample compared to national data. A slight majority of this sample was female (n=102, 51%);
whereas, men were represented as the majority (n=854,790, 51%) in national data of new cancer
cases (Siegel, Ma, Zou, & Jemal, 2014). Of note, the national data takes into account all ages of
cancer cases, not just older adults. The mean age of participants in this sample was 73.10 years,
which is consistent with national data that cancer rates are highest in people aged 65-74 years
(National Cancer Institute, 2013). Unlike national data, the majority of this sample (88.8%) was
white (Siegel et al., 2014). Complex decisions related to chemotherapy and radiation therapy
accounted for the majority of the sample (n=169, 84.9%). This is not surprising given that
treatment-related side effects of chemotherapy and radiation therapy can vary greatly and can
have a negative effect on the natural history of cancer (Balducci, 2009; Extermann, 2007; Muss,
2009; Zeber et al., 2008).
Family members were a source of support for the participants in this study. Over seventyfive percent of the sample indicated that they were accompanied to appointments with their
cancer doctors by a spouse/significant other, child, or other family member. Only 19% of the
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sample went to cancer-related appointments alone. The availability of a caregiver or a family
member influences treatment decisions (Kreling, Figueiredo, Sheppard, & Mandelblatt, 2006)
and, to some extent, can lead to disagreement among family members (Schafer et al., 2006;
Zhang & Siminoff, 2003). Family support was also essential in making decisions about cancer
treatment. In this sample, participants reported multiple sources of support in making decisions
about cancer treatment. The most frequent including cancer doctor (99%), family (80%), and
cancer nurse (37%). This is consistent with other studies that demonstrated the importance of
family preference, family burden, and physician’s opinion in making cancer-related treatment
decisions (Kohara & Inoue, 2010; Kutner, Vu, Prindiville, & Byers, 2000).
According to O’Connor (2010), a DCS score less than 25 indicates no decision-making
difficulty. The mean DCS total score of 22.1 demonstrated that, overall, the participants in this
study did not have difficulty with decision making. This result should be interpreted cautiously
however, given the finding by Chien, Chuang, Liu, Li, and Liu (in press) that DCS scores
reduced considerably up to six months post-treatment. Since almost 63% of the sample made
the treatment-related decision within the last six months, the actual level of decisional conflict
may have been higher at the time of the decision. Participants did demonstrate a higher level of
decisional conflict in DCS subscale four which evaluates how informed one is “about options,
risks, and benefits, and feeling clear about values and value tradeoffs in the decision” (O'Connor,
1995, p. 26). A higher score in this subscale indicates that participants felt less informed about
options, risks, and benefits and were unsure of personal values in making cancer treatmentrelated decisions (O'Connor, 1995).
When compared with data from other studies of older adults with cancer, the global health
status/QOL of this sample was generally poorer. In this study, the mean score on the two global
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health status/QOL questions was 44.2 (Range = 0.0 - 100.0), with a higher score representing a
higher QOL. In a large study of cancer patients by Scott et al. (2008) to establish reference
values for the EORTC QLQ-C30, the mean global health status/QOL was found to be 61.8 (ages
60-69) and 60.6 (ages 70 and older). Although different instruments were used to measure QOL,
the overall QOL of this sample is poorer than the QOL of older adults with cancer or advanced
illness in other studies (Black et al., 2011; Solomon, Kirwin, Van Ness, O'Leary, & Fried, 2010).
When compared with the EORTC QLQ-C30 reference values (Scott et al., 2008) for
patients 70 years and older, the participants in this study had poorer physical function, poorer
role function, better emotional function, similar cognitive function, and poorer social function.
With the exception of insomnia, the participants in this study had higher mean scores on all
symptom scales and single items than the EORTC QLQ-C30 reference values. The mean
insomnia scores were similar. The fact that participants in this study, overall, had poorer role
function and worse symptomatology may account for the poorer global health status/QOL.
The reported level of comorbidity by participants in this study was higher than in other
studies of older adults that utilized the SCQ (Merriman et al., in press; Schjolberg et al., 2011).
The most reported comorbid illnesses were similar to the most reported illnesses in other studies
of older adults, including high blood pressure, back pain, and lung disease (Sangha et al., 2003;
Sarna et al., 2005; Schjolberg, Dodd, Henriksen, & Rustoen, 2011).
Correlational analysis indicated that decisional conflict as measured by DCS total was
significantly correlated with QOL, as measured by global health status/QOL. The weak, though
positive and significant, correlation indicates that greater treatment-related decisional conflict
may be associated with greater QOL. Fried, Bradley, Towle, and Allore (2002) found that older
adults with cancer chose their treatment decisions depending on the burden of the treatment,
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possible outcomes, and likelihood of adverse functional and cognitive outcomes. However, to
date, there have been no published reports of the relationship between decisional conflict and
QOL. Additional studies are needed to validate the findings in this study.
Correlational analysis indicated that QOL, as measured by global health status/QOL, was
significantly correlated with comorbidity, as measured by SCQ. The weak to moderate, though
positive, correlation indicates that greater QOL may be associated with greater comorbidity.
This is contradictory to a study of lung cancer patients that demonstrated severe comorbidity to
be associated with poor QOL (Gronberg et al., 2010). It is important to note, however, that the
instrument used to measure comorbidity was different than that used in this study.
Correlational analysis indicated that decisional conflict, as measured by DCS total, and
comorbidity, as measured by SCQ, were not significantly correlated. In this study, the SCQ was
not found to have an acceptable level of internal consistency (α=.358) and, thus, a Type II error
may have occurred.
Statistical significance was found with respect to emotional function in all six regression
models. As emotional function scores increased, scores decreased in DCS total, informed
subscale, values clarity subscale, support subscale, uncertainty subscale, and effective decision
subscale. Simply, these findings indicate that higher/healthier emotional function may be
predictive of lower decisional conflict. Additionally, with regard to the subscales,
higher/healthier emotional function may be predictive of feeling informed about options, risks,
and benefits; being clear about personal values; feeling supported in decision making; feeling
certain about decision; and feeling that an effective decision has been made.
Previous studies have documented a relationship between decisional conflict and
emotional status, with mixed results. In a study of hospital patients (Knops et al., 2013), the
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investigators found that a decrease in decisional conflict lead to less fretting and nervousness.
Rini et al. (2009) found a similar relationship to the present study with a significant negative
predictive relationship between anxiety and DCS.
Financial problems, reported as a component of the EORTC QLQ-C30, were statistically
significant in the regression models for DCS total, the informed subscale, and the uncertainty
subscale. There was a significant positive relationship documented, with financial problem
scores increasing as DCS total, informed subscale, and uncertainty subscale scores increased.
This indicates that financial problems may be predictive of higher decisional conflict, overall, as
well as in the two subscales. Poor financial status and a lack of insurance are important
contextual factors that can influence treatment choice (Bailey et al., 2003; Mandelblatt et al.,
1999; Schrag et al., 2001).
Interestingly, significant inverse relationships were found between physical symptoms
reported as components of the EORTC QLQ-C30, including diarrhea, insomnia, fatigue, nausea,
and vomiting. This is a curious finding, as it would seem that worse physical symptoms,
especially if they were treatment-related, may increase decisional conflict. Although an
explanation for this finding is unclear, it may be that participants felt that the symptoms are
expected with the cancer treatment and, thus, did not increase conflict in the decision making
process. Alternatively, if the symptoms are cancer-related, participants may have felt that the
treatment was helping them. The progression of time that had occurred between when the
decision had been made and when the survey was completed may have also had an impact on the
result. In prior studies, the presence of spiritual support has been documented to impact
treatment-related decisions (Balboni et al., 2010; True et al., 2005). In this study, the use of a
spiritual support person for decision making, which is reported as a component of the
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demographic information form, significantly decreased scores in the informed and effective
decision subscales. There are no published studies examining the relationship between spiritual
support and decisional conflict; however, the results of this study are suggestive of spiritual
support lowering the informed and effective decision components of decisional conflict.
5.7

Limitations
There are several limitations that impact the generalizability of the findings of this study.

It is important to recognize that these data are reflective of a group of predominantly white
cancer patients from a suburban area in the Northeastern United States and are not representative
of the nation as a whole. Therefore, the results of this study may not be generalizable to
individuals with different demographic characteristics. All of the data utilized in this study was
self-reported, which could impact the accuracy of the data. Although study participation was
voluntary and anonymous, it is possible that not all participants were comfortable exploring
some of the psychosocial or emotional components of the surveys. Since most of the participants
reported that they do not go to their appointments alone, the surveys may have been completed in
the presence of someone else. This may have affected their responses. Furthermore, with
regard to comorbidity, it is possible that the SCQ was not the best instrument to use in this this
population given the low Cronbach’s alpha.
5.8

Implications for nursing
This study examined the relationship between decisional conflict, QOL, and comorbidity

in older adults with cancer. Nurses are an important part of the multidisciplinary cancer team
and can have a critical impact on patients’ cancer journey. Nursing is integral in helping to meet
the recent goals set forth by the Institute of Medicine (IOM) (2013) for high-quality cancer care.
One of the goals identified by the IOM (2013) is to engage patients by providing patients and
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their families with understandable information on cancer prognosis, treatment benefit and harms,
psychosocial support, and estimates of the total and out-of-pocket costs of cancer care.
Participants in this study were found to experience decisional conflict in the uncertainty subscale,
have poor quality of life, and suffer with a cancer and treatment-related symptoms. Since
patient-centered care is at the core of nursing practice, nurses are poised to empower patients to
communicate their needs, values, and preferences about cancer treatment (Ferrell, McCabe, &
Levit, 2013).
As this study illustrates, cancer is often only one of several comorbid conditions among
older adults. It is imperative that nurses who care for older adults with cancer, as well as the
entire multidisciplinary team, have expertise in geriatric principles. It is crucial that nurses are
prepared to provide high-quality care to complex patients with regard to cognitive impairment,
management of comorbidities, maintenance of functional status, and prevention of falls (Ferrell
et al., 2013; Hurria, Naylor, & Cohen, 2013).
5.9

Future Research
Research reports that focus on older adults with cancer are limited. This was the first

study known to examine the variables of decisional conflict, QOL, and comorbidity in older
adults. Future research should focus on additional investigation of these variables, particularly
with a diverse sample representative of the national cancer statistics, and to further validate these
study results. Since decisional conflict can diminish over time (Chien et al., in press), it would
be helpful to repeat this study with patients who are currently in the process of making a
treatment-related decision and, possibly, prospectively follow them over a period of time. In
light of the results of the regression analyses, further research is needed to better understand
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emotional function, spiritual support, and symptom management in the setting of decision
making in older adults with cancer.
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Appendix A
Decisional Conflict Scale (DCS)
Considering the option you prefer, please answer the following questions:
Strongly
Agree

Agree

[0]

[1]

1. I know which options are available to
me.
2. I know the benefits of each option.
3. I know the risks and side effects of
each option.
4. I am clear about which benefits
matter most to me.
5. I am clear about which risks and side
effects matter most.
6. I am clear about which is more
important to me (the benefits or the
risks and side effects).
7. I have enough support from others to
make a choice.
8. I am choosing without pressure from
others.
9. I have enough advice to make a
choice.
10. I am clear about the best choice for
me.
11. I feel sure about what to choose.
12. This decision is easy for me to
make.
13. I feel I have made an informed
choice.
14. My decision shows what is
important to me.
15. I expect to stick with my decision.
16. I am satisfied with my decision.
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Neither
Agree
Or
Disagree
[2]

Disagree

Strongly
Disagree

[3]

[4]

Appendix B
Self-Administered Comorbidity Questionnaire (SCQ)
Instructions:
The following is a list of common problems. Please indicate if you currently have the problem in the first column.
If you do not have the problem, skip to the next problem.
If you do have the problem, please indicate in the second column if you receive medications or some other type of
treatment for the problem.
In the third column indicate if the problem limits any of your activities.
Finally, indicate all medical conditions that are not listed under “other medical problems” at the end of the page.
Do you have the
Do you receive treatment
Does it limit your
PROBLEM
problem?
for it?
activities?
No
Yes 
No
Yes
No
Yes
(0)
(1)
(0)
(1)
(0)
(1)
Heart disease

N

Y

N

Y

N

Y

High blood pressure

N

Y

N

Y

N

Y

Lung disease

N

Y

N

Y

N

Y

Diabetes

N

Y

N

Y

N

Y

Ulcer or stomach
disease

N

Y

N

Y

N

Y

Kidney disease

N

Y

N

Y

N

Y

Liver disease

N

Y

N

Y

N

Y

Anemia or other
blood disease

N

Y

N

Y

N

Y

Cancer

N

Y

N

Y

N

Y

Depression

N

Y

N

Y

N

Y

Osteoarthritis,
Degenerative arthritis

N

Y

N

Y

N

Y

Back pain

N

Y

N

Y

N

Y

Rheumatoid arthritis

N

Y

N

Y

N

Y

Other medical problems
(please write in)

N

Y

N

Y

N

Y

N

Y

N

Y

N

Y

N

Y

N

Y

N

Y

105

Appendix C
From:
Sent:
To:
Subject:

Katz, Jeffrey Neil, M. D.
January 28, 2012 9:20 PM
katesj@duq.edu
Self-Administered Comorbidity Questionnaire

Feel free to use it, Jeannette. Simply cite the AC&R reference
in your studies.
Good luck,
Jeff
Jeffrey N. Katz, MD, MS
Professor of Medicine and Orthopaedic Surgery
Brigham and Women's Hospital, OBC - 4
75 Francis Street
Boston, MA 02115
phone 617-732-5338; fax 617-525-7900
jnkatz@partners.org
http://www.brighamandwomens.org/research/labs/oracore/default.as
px
________________________________
From: Jeannette Kates [mailto:katesj@duq.edu]
Sent: Sat 1/28/2012 4:42 PM
To: Katz, Jeffrey Neil, M.D.
Subject: Self-Administered Comorbidity Questionnaire
Dr. Katz,
I am a PhD student in the School of Nursing at Duquesne
University. I am
interested in using the SCQ in my dissertation research on
treatment-related
decisional conflict, quality of life, and comorbid illness in
older adults with
cancer. Please advise as to how I can gain permission to do so.

Thank you,

Jeannette Kates
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Appendix D
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire
(EORTC QLQ-C30)
We are interested in some things about you and your health. Please answer all of the questions yourself by
circling the number that best applies to you. There are no "right" or "wrong" answers. The information that you
provide will remain strictly confidential.
Not at
A
Quite
Very
All
Little
A Bit
Much
1. Do you have any trouble doing strenuous activities, like
1
2
3
4
carrying a heavy shopping bag or a suitcase?
2. Do you have any trouble taking a long walk?
1
2
3
4
3. Do you have any trouble taking a short walk outside of
1
2
3
4
the house?
4. Do you need to stay in bed or a chair during the day?
1
2
3
4
5. Do you need help with eating, dressing, washing yourself
1
2
3
4
or using the toilet?
During the past week:
6. Were you limited in doing either your work or other daily
1
2
3
4
activities?
7. Were you limited in pursuing your hobbies or other
1
2
3
4
leisure time activities?
8. Were you short of breath?
1
2
3
4
9. Have you had pain?
1
2
3
4
10. Did you need to rest?
1
2
3
4
11. Have you had trouble sleeping?
1
2
3
4
12. Have you felt weak?
1
2
3
4
13. Have you lacked appetite?
1
2
3
4
14. Have you felt nauseated?
1
2
3
4
15. Have you vomited?
1
2
3
4
16. Have you been constipated?
1
2
3
4
17. Have you had diarrhea?
1
2
3
4
18. Were you tired?
1
2
3
4
19. Did pain interfere with your daily activities?
1
2
3
4
20. Have you had difficulty in concentrating on things, like
1
2
3
4
reading a newspaper or watching television?
21. Did you feel tense?
1
2
3
4
22. Did you worry?
1
2
3
4
23. Did you feel irritable?
1
2
3
4
24. Did you feel depressed?
1
2
3
4
25. Have you had difficulty remembering things?
1
2
3
4
26. Has your physical condition or medical treatment
1
2
3
4
interfered with your family life?
27. Has your physical condition or medical treatment
1
2
3
4
interfered with your social activities?
28. Has your physical condition or medical treatment caused
1
2
3
4
you financial difficulties?
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For the following questions please circle the number between 1 and 7 that best applies to you

29. How would you rate your overall health during the past week?
1
2
3
4
5
6
7
Very poor
Excellent
30. How would you rate your overall quality of life during the past week?
1
2
3
4
5
6
7
Very poor
Excellent
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Appendix E
From:
Sent:
To:
Subject:

qlqc30@eortc.be
August 27, 2011 5:52 PM
katesj@duq.edu
QLQ-C30 download request from Jeannette Kates

Dear Sir/Madam,
Please find below the links where you can download the documents
you requested.
Best regards,
Your data:
Title: Mrs.
Firstname: Jeannette
Lastname: Kates
Hospital/Institution: Duquesne University
Address: 17 Creekside Trail
County/State: NJ
Postal Code: 08076
Country: United States of America
Phone: 8568405866
Fax:
Email: katesj@duq.edu
Protocol: unknown
Documents requested:
QLQ-C30 Core Questionnaire in English
QLQ-C30 Scoring Manual
Addendum scoring instructions validated modules
URLs:
http://www.eortc.be/home/qol/files/C30/QLQ-C30%20English.pdf
http://www.eortc.be/home/qol/files/SCManualQLQ-C30.pdf
http://www.eortc.be/home/qol/files/Addendum_scoring_instructions
.pdf
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Appendix F
Demographic Information Form (DIF)
DIRECTIONS: Please complete the following information.
1.

AGE: _____
DATE OF BIRTH: ___/___/___

2.

GENDER:
__Male
__Female

3.

CURRENT MARITAL STATUS:
__Single (never been married)
__Married
__Separated
__Divorced
__Widowed

4.

RACE AND/OR ETHNIC ORIGIN:
__Native American/Eskimo
__Asian
__African American
__Hispanic
__White
__Other, Please Specify ____________

5.

RELIGION:
__Catholic
__Jewish
__Protestant
__None
__Other, Please Specify ____________

6.

EMPLOYMENT STATUS:
__Retired
__Employed Full Time
__Employed Part Time
__Disabled

7.

EDUCATION:
What is the highest grade or year you completed? __________
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8.

HEALTH:
Please list all of the prescription and over-the-counter medications you are currently taking:
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________

9.

What type of cancer do you have?
______________________________________

10. When were you diagnosed?
Month________ Year________
11. Have you been told the cancer has spread anywhere?
12. Have you ever received chemotherapy?

NO

YES

13. Have you ever received radiation therapy? NO

YES

14. Have you ever had surgery for your cancer? NO

NO

YES

YES

15. Do you typically go to appointments with your cancer doctor alone? NO

YES

If NO, who goes with you? ________________
16. What decision(s) related to your treatment have you had to make or still have to make?
__Chemotherapy
__Radiation therapy
__Surgery
17. Which of the following resources/support/decision aids are helpful to you in making decisions about your
cancer treatment? (please check all that apply)
__Cancer doctor
__Cancer nurse
__Family
__Priest/minister/spiritual support person
__Books
__Websites
__Support group
__Other _____________________
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Appendix G
Pilot Study Institutional Review Board Approval

DUQUESNE
UNIVERSITY
Office of Research

301 ADMINISTRATION BUILDING  PITTSBURGH, PA 15282-0202
Dr. Joseph C. Kush
Chair, IRB-Human Subjects
Office of Research
Phone (412) 396-6326 Fax (412) 396-5176
E-mail: kush@duq.edu

October 2, 2012
Re: A Pilot Study to Determine the Usability of the Decisional Conflict Scale in Older
Adults with Cancer – (PROTOCOL # 12-107)
Dr. Linda Goodfellow
School of Nursing
Duquesne University
Pittsburgh PA 15282
Dear Dr. Goodfellow,
Thank you for submitting the research proposal of you and your student Jeannette Kates to the
Institutional Review Board at Duquesne University.
After review by IRB members Dr. Carolyn J. Nickerson, along with the entire Board, the study
is approved under the federal Common Rule, specifically 45-Federal Code of Regulations
#46.101 and 46.111. Additionally, your study has been approved, as HIPAA compliant, by
Dr. Joan Kiel.
The consent form is attached, stamped with IRB approval and expiration date. You should use
the stamped form as the original for copies you display or distribute.
This approval will be renewed in one year as part of the IRB’s continuing review. You will
need to submit a progress report to the IRB at the address shown above. The report will
involve supplying answers to a number of questions that will be sent to you. In addition, if
you are still using assent/permission forms, you will need to obtain renewed approvals. In
correspondence about this study, please refer to the protocol number shown after the title
above.
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If, prior to the annual review, you or Ms. Kates propose any changes in your procedure you
must inform the IRB Chair of those changes and wait for approval before implementing them.
In addition, if any unanticipated problems or adverse effects on subjects are discovered before
the annual review, they immediately must be reported to the IRB Chair before proceeding
with the study.
When the study is complete, please provide the IRB with a summary, approximately one page.
Often the completed study’s Abstract suffices. Keep a copy of your research records, other
than those you have agreed to destroy for confidentiality, over a period of five years after the
study’s completion.
Thank you for contributing to Duquesne’s research endeavors.

Sincerely yours,

Joseph C. Kush, Ph.D.
C: Dr. Carolyn J. Nickerson Dr.
Joan Kiel
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Appendix H
Participant Consent for Pilot Study
Duquesne University IRB - Protocol 12-107
Approval Date: October 2, 2012
Expiration Date: October 2, 2013

CONSENT TO PARTICIPATE IN A
RESEARCH STUDY
A pilot study to determine the usability of the Decisional Conflict Scale (DCS) in older
adults with cancer

INVESTIGATOR:

Jeannette M. Kates, MSN, RN, PhD Candidate
Duquesne University School of Nursing
17 Creekside Trail
Delran, NJ 08075
856-840-5866
Dr. Linda Goodfellow Associate Professor
Duquesne University School of
Nursing 310 Fisher Hall
Pittsburgh, PA 15282
412-396-6548

SOURCE OF SUPPORT:
fulfillment of

This pilot study is being performed as partial

the requirements for the doctoral degree in nursing at Duquesne University.
You have been invited to participate in a pilot study for a nursing research study that seeks to
understand cancer treatment-related decisional conflict in older adults with cancer. This pilot
study will test the survey known as the Decisional Conflict Scale (DCS). This survey
measures patients’ uncertainty in making healthcare decisions, factors contributing to the
decision, and how effective patients perceive their decisions to be. Although this is not a
new survey, the instructions included prior to the study are new. The purpose of this pilot
study is to test if the wording of the instructions is clear and if the size and style of the font is
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easy to read. If you agree to participate, you will be asked to complete the survey on paper.
In order for me to determine how clear the instructions are and how easy the font is to read, it
is necessary for me to sit in the same room as you to complete the survey. I will encourage
you speak your thoughts out loud as you complete the survey. Additionally, I will encourage
you to point out to me anything within the instructions or survey is not clear or that you do
not understand. Your survey responses will be discarded as soon as the pilot study is
complete—approximately two to four weeks. I will not record any personal information
which could identify you. Since your participation in the pilot study is confidential and your
survey responses will be discarded, you will be eligible to participate in the primary study
when it is made available.
You are being asked to participate in this study because you are at least 65 years of age,
English speaking, are receiving treatment for your cancer, and have the ability to read
English at an eighth grade level. Your participation requires completion of a 16 question
survey. It is anticipated that 5 to 10 patients with cancer will complete this pilot study.

RISKS AND BENFITS:

COMPENSATION:

CONFIDENTIALITY:

There is no more risk in participating in this study than
what you experience in everyday life. There are no
direct benefits to participating in this study other than
the satisfaction in knowing that this information may
someday help someone like you. Due to the topic
being studied, it is possible that you may feel
uncomfortable when completing the questionnaire. If
you do, you may take a brief break or stop completing
the survey. In addition, if you should feel tired while
participating in the study, you may stop and rest at any
time.
There is no compensation available to you for
participation in this study. Participation in this study will
require no monetary cost to you.
Your name will never appear on any survey or research
instruments. Your responses will be discarded and not
utilized for data analysis, as described above. The only
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information that will be recorded is any feedback or comments you make about the survey
during survey completion or immediately after you finish the survey. Following the
completion of the study, all data will be stored securely for a period of five years. All
materials will be destroyed at the completion of the five years.

RIGHT TO WITHDRAW:

You are under no obligation to participate in this pilot
study. You are free to withdraw from this study at any time. If you choose not to participate
in this study, your healthcare will not be impacted in any manner.

SUMMARY OF RESULTS: A summary of the results of this pilot will be supplied to
you, at no cost, upon request.

VOLUNTARY CONSENT:

I have read the above statements and understand what is
being requested of me. I also understand that my participation is voluntary and that I am free
to withdraw my consent at any time, for any reason. On these terms, I certify that I am
willing to participate in this research project.
I understand that should I have any further questions about participation in this study, I may
call Jeannette Kates, Principal Investigator (856-840-5866), Dr. Linda Goodfellow, Chair of
Dissertation Committee (412-396- 6548), or Dr. Joseph Kush, Chair of the Duquesne
University Institutional Review Board (412-396-6326).

I consent to participate in the research described in this form.
Name of Subject:

_

Signature of Subject:
Date:
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Appendix I
Main Study Institutional Review Board Approval

DUQUESNE
UNIVERSITY
Office of Research

301 ADMINISTRATION BUILDING  PITTSBURGH, PA 152820202
Dr. Joseph C. Kush
Chair, IRB-Human
Subjects Office of
Research
Phone (412) 396-6326 Fax (412) 396-5176
E-mail:
kush@duq.edu

November 6, 2012
Re: Treatment-related decisional conflict, quality of life, and comorbid illness in older
adults with cancer – (PROTOCOL # 12-146)
Dr. Linda Goodfellow
School of Nursing
Duquesne University
Pittsburgh PA 15282
Dear Dr. Goodfellow,
Thank you for submitting the research proposal of you and your student Jeannette Kates to the
Institutional Review Board at Duquesne University.
Based on the review of IRB representative Dr. L. Kathleen Sekula and my own review, your
study is approved as Exempt based on 45-CFR-46.101.b.2 regarding research involving the
use of educational tests, survey procedures, interview procedures or observations of public
behavior. Additionally Dr. Joan Kiel has reviewed your protocol and determined it to be
HIPAA compliant.
The consent form is attached, stamped with IRB approval and expiration date. You should use
the stamped forms as the original for copies you display or distribute.
The approval pertains to the submitted protocol. If you or Ms. Kates wish to make changes to
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the research, you must first submit an amendment and receive approval from this office. In
addition, if any unanticipated problems arise in reference to human subjects, you should notify
the IRB chair before proceeding. In all correspondence, please refer to the protocol number
shown after the title above.
Once the study is complete, please provide our office with a short summary (one page) of your
results for our records.
Thank you for contributing to Duquesne’s research
endeavors. Sincerely yours,

Joseph C.
Kush, Ph.D.
C: Dr. L. Kathleen
Sekula Dr. Joan Kiel
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Appendix J
Participant Cover Letter for Main Study
Duquesne University IRB Protocol 12-146
Approval Date: November 6, 2012
Expiration Date: November 6, 2013

Dear Potential Participant,
If you currently have cancer, are at least 65 years of age, have at least an eighth
grade education, and are interested in participating in this study, please read the
following.
You are being asked to participate in a research project that seeks to investigate
conflict in decision making (related to your cancer treatment), quality of life, and
comorbidity. This research project also seeks to investigate any relationships that
may exist between conflict in decision making, quality of life, and comorbidity.
The term comorbidity means any illness or health problem that you have in
addition to cancer.
Participation in this study will require you to answer some questions about your
background, your health problems, your quality of life, and decision making
associated with cancer treatment. It will take approximately 40 minutes of your
time to complete these questions. Once you have completed these questions, you
are asked to return them to the nurse in the doctor’s office where you received the
packet. Do not put your name on any of the questionnaires or the return envelope.
These are the only requests that will be made of you.
There is no more risk in participating in this study than what you experience in
everyday life. There are no direct benefits to participating in the study other than
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the satisfaction in knowing that this information may someday help someone else
like you. A $10 gift card has been included in this packet, which is compensation
for your participation in this study. Participation in this project will require no
monetary cost to you.
You will not be asked to give your name, address, or any other identifying
information. Since I will not know your name, your name will never appear on
any questionnaire or research instruments and you will not be identified in the data
analysis. All written materials and consent forms will be stored in a locked file in
the researcher's office. Your responses will only appear in statistical data
summaries. All materials will be stored for five years and then destroyed at the
completion of the research.
You are under no obligation to participate in this study. By completing the
questionnaires and then returning them to the researcher, you are providing consent
to participate in this research project. You are free to withdraw your consent to
participate at any time by not completing or returning the questionnaires to the
researcher. Your medical care will not be affected if you do not participate in this
research project.
If you have questions about participation in this study, you may contact Dr. Linda
Goodfellow, Chair of Dissertation Committee at 412-396-6548, or Dr. Joseph
Kush, Chair of the Duquesne University Institutional Review Board, at 412-3966326.
If you are interested in participating in this study, please take one of the
questionnaire packets. Once you have completed it, please return it to the front
desk of this doctor’s office.
Sincerely,
Jeannette Kates, MSN, APN-C, GNP-BC
PhD Candidate, Duquesne University School of Nursing
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